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Abstract 
Targeting of the epidermal growth factor receptor (EGFR) has become an established 
antitumor strategy with anti-EGFR antibodies approved for clinical use or in late stages of 
development. Postulation of antibody effector mechanisms has been based on in vivo or cell 
studies. These need to be complemented by an understanding of antibody/EGFR interactions 
on the molecular level. Thereon, crystal structures of the Fab fragments from different 
inhibitory antibodies in complex with the extracellular regions of EGFR have enlightened the 
molecular basis behind antibody-mediated EGFR inhibition. This study was focused on the 
further in vitro characterization of antibody/EGFR complexes in terms of stoichiometry, 
kinetics and thermodynamics of binding. Surface plasmon resonance (SPR)/Biacore, 
isothermal titration calorimetry (ITC) and static light scattering (SLS) were the tools 
employed to characterize the interactions between anticancer monoclonal antibodies and the 
epidermal growth factor receptor (EGFR). Clear stoichiometric evidence is provided for the 
binding of the monoclonal antibodies matuzumab, cetuximab and panitumumab to EGFR. 
These three antibodies are able to bind two EGFR molecules simultaneously, thus forming 
heterotrimer complexes. Independency of the two simultaneous EGFR binding events to one 
antibody molecule was confirmed with both kinetic and thermodynamic evidence. 
Unexpected stoichiometry results obtained for the nimotuzumab/EGFR interaction strongly 
indicate partial inactivity of the binding sites of this marketed antibody solution. Kinetically, 
the strong affinities of cetuximab and panitumumab could be related, respectively, to fast 
association and slow dissociation rates for the interactions of these two antibodies with 
EGFR. Similarly, the lower affinity of matuzumab could be assigned to a very fast 
dissociation of the matuzumab/EGFR complex. As for nimotuzumab, the lower affinity was 
mainly the result of a slower association rate to EGFR. Thermodynamically, the lower affinity 
known for matuzumab could be assigned to a higher entropic penalty upon binding. 
Interestingly, similar strong affinities of cetuximab and panitumumab were resolved to 
somewhat different thermodynamic profiles. Respectively, cetuximab interaction involves a 
higher enthalpy change compensated by an entropic penalty, while panitumumab interaction 
involves the lower enthalpy contribution of all four antibodies and an entropy change close to 
zero. All antibody/EGFR interactions were enthalpy-driven with either an entropy penalty or 
an entropy change close to zero. In contrast, interactions of the agonistic ligands EGF and 
TGF-α with EGFR were entropy driven and enthalpy penalised. Such different 
thermodynamic profiles are indicative of different binding processes for inhibitory antibodies 
and agonistic ligands. 
 
Motivated by reports on synergetic effects of the combined use of different EGFR-targeting 
antibodies, studies of the interdependent binding of antibody combinations to EGFR delivered 
insights into allosterism and relative epitope mapping. Results presented strongly corroborate 
the simultaneous binding of the antibody combinations matuzumab/cetuximab and 
matuzumab/nimotuzumab to EGFR. Concerning the binding of the combinations 
matuzumab/panitumumab, nimotuzumab/cetuximab and nimotuzumab/panitumumab to 
EGFR, displacement of the first antibody present upon binding of the second was observed. 
SPR results indicate that displacement of the first antibody could be caused by small 
conformational shifts upon binding of the second antibody. 
 
The applicability of the biophysical methods used for the generation of meaningful 
quantitative data on binding interactions is demonstrated. Furthermore, a comparative 
assessment of the biophysical tools SPR, ITC and SLS to the study of protein-protein 
interactions is presented. The possibility of real time monitoring of the interactions was a 
special feature of SPR that enabled determination of the binding kinetics. Since SPR analysis 
involves immobilization of one interactant, it is not necessarily representative of what 
happens in solution. However, thermodynamic characterization of antibody interactions with 
EGFR performed with SPR delivered enthalpy and entropy changes that correlate well with 
ITC results. In fact, EGFR being a membrane protein, the adequacy of a solution method such 
as ITC to be more representative of the in vivo situation than a surface method such as SPR 
could be contested. The results presented rather demonstrate the combined utilities and 
corroborative use of SPR and ITC, with SLS providing an additional qualitative confirmation 
of the assembly states. 
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1 0BAIM OF THE THESIS  
Cancer patients often suffer from serious side effects of chemo- and radiotherapy treatment to 
combat the uncontrolled proliferation in malignant tumors. Targeted therapy, such as 
therapeutic antibodies directed against specific cancer related cell surface proteins, might 
offer a more efficient treatment. One of these cancer related cell surface proteins is the 
epidermal growth factor receptor (EGFR). EGFR is aberrantly activated in a variety of 
epithelial tumors – colon, breast, lung, pancreas, head and neck – and is a target in anti-cancer 
therapy. In 2004, Erbitux/cetuximab (Merck KGaA) was the first FDA-approved anti-EGFR 
monoclonal antibody. Cetuximab is a chimera, i.e., a hybrid structure made by the fusion of 
murine variable regions and human conserved regions of the antibody structure. The antibody 
technology production has evolved very fast in the past years in the direction of reducing the 
percentage of murine sequence, which may lead to immunogenicity. Vectibix/panitumumab 
(Amgen) is an anti-EGFR fully human antibody, the second to be approved by the FDA in 
2006. Theracim/nimotuzumab (YM Biosciences) is a humanized antibody approved in several 
countries in the world with reported exemplary low side effects occurrence. Apart from these 
three marketed antibodies, many others are in advanced stages of pharmaceutical 
development. 
 
Despite the fast growing clinical use of monoclonal antibodies in the oncology field, their 
mechanisms of tumor inhibition are often not yet fully understood. It is known that anti-EGFR 
antibodies interact with the extracellular region of the receptor, thereby interfering with the 
EGFR-dependent signalling that is involved in cellular processes crucial for growth and 
differentiation. Postulation of mAbs effector mechanisms has been based on in vivo or cell 
studies. These need to be complemented by an understanding of mAb/EGFR interactions on 
the molecular level. Thereon, crystal structures have delivered valuable information about the 
molecular interfaces formed between mAbs and their EGFR epitopes. Studies of the kinetics 
and thermodynamics of binding can provide a more complete understanding of the forces that 
lead to complex formation and the dynamics of the interaction.  
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Surface plasmon resonance, isothermal titration calorimetry and static light scattering were 
the biophysical tools employed to study the biomolecular interactions of EGFR with four 
therapeutic monoclonal antibodies and two natural ligands. The applicability of the innovative 
biophysical methods used for the generation of meaningful quantitative data about binding 
interactions is demonstrated. The high quality data generated provided quantitative evidence 
to answer the following questions related to antibody/EGFR interaction: 
• How many EGFR molecules can one antibody bind simultaneously? 
• How fast do the molecules bind? 
• How long does the complex last? 
• How strong is the interaction? 
• Why does it take place, what are the thermodynamic reasons that drive the interaction? 
 
Answers to those questions were generated and provided highly resolved definition of the 
macromolecular interactions studied in terms of assembly state, affinity, kinetics and 
thermodynamics of complex formation. Added to this, studies of binding interdependence of 
antibody combinations to EGFR delivered insights into epitope and allostery mapping with 
interesting application for combination therapeutic strategies. Cell surface assays and clinical 
investigations were beyond the scope of this thesis and results are discussed based on 
literature. 
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2 1B IOPHARMACEUTICALS 
2.1 9BIntroduction 
Biopharmaceuticals are proteins, peptides, viruses and DNA-based products used for 
therapeutic or diagnostic use (Wu-Pong and Rojanasakul, 2008). They can be, and usually are, 
obtained by biotechnology. Biotechnology as an industry emerged in the 1970s, based largely 
in the discovery of recombinant DNA technology by Cohen and Boyer (Cohen et al., 1973). 
One of the biggest breakthroughs in biotechnology happened in the manufacture of 
recombinant human insulin (Sun, 1980; Johnson, 1983). In 1982, insulin became the first 
medicine made via recombinant DNA technology to be approved by the FDA. When 
compared to animal purified insulin, recombinant human insulin had advantages in terms of 
costs, safety and supply. Its successful establishment as routine diabetes therapy was a 
milestone that contributed to the acceptance of recombinant DNA technology. As a matter of 
fact, since then biotechnology has created more than 200 new therapies and vaccines based on 
recombinant DNA, and other 400 are currently in clinical trials (Biotechnology Industry 
Organization, 2008). Target diseases include cancer, Alzheimer’s disease and autoimmune 
and inflammatory disorders.  
 
The first protein biopharmaceuticals were already existing human proteins, whose shortage in 
the body was responsible for disease. These included insulin as well as human growth 
hormone, and erythropoietin. In the era of the human genome project, with the emergency of 
the fields of genomics and proteomics, scientists could identify genes implicated in disease. 
Novel-designed drugs, like monoclonal antibodies, could thus be developed against specific 
disease-related targets. Monoclonal antibodies are genetically engineered and thus unique and 
novel to the cell. However, they are still basically the same in structure as other human 
antibodies. The next step was the development of completely novel scaffolds, bearing less and 
less resemblance to existing human proteins (Projan et al., 2004). Examples of these new 
scaffolds are immunoglobulin-type molecules developed on the basis of modular construction 
of single variable domain antibodies (Gill and Damle, 2006). Evolution in the field of 
biotechnology has thus shaped the design and development of novel biopharmaceuticals. In 
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the future, biotechnology is expected to play a more and more important role in healthcare, if 
individualized disease prevention and treatment come true (Biotechnology Industry 
Organization, 2008; Wu-Pong and Rojanasakul, 2008). Genetic analysis will enable drugs to 
be designed specifically for groups of people with similar genetic profiles. The breast cancer 
drug Herceptin (trastuzumab) is an example of a pharmacogenomic drug. Initially approved in 
1998, Herceptin targets and blocks the HER2 protein receptor, which is overexpressed in 
some aggressive cases of breast cancer. A test can identify which patients are overexpressing 
the receptor and can benefit from the drug. In 2005, FDA approved for the first time a drug 
for a specific race: BiDil treats congestive heart failure in self-identified black patients.
 
2.2 10BMonoclonal antibodies 
One of the fastest growing biopharmaceuticals is the monoclonal antibody, which is now used 
to treat diseases mainly in oncology and auto-immune and infectious diseases segments. 
Antibodies are bifunctional molecules (Congy-Jolivet et al., 2007; Peipp et al., 2008). On one 
hand, they recognize their antigen through the variable regions of the antigen binding portion 
(Fab). As a result, they may interfere with one or several functions of this antigen, leading to 
the therapeutic effect. On the other hand, through the constant regions (Fc) they may interact 
with Fc-binding molecules and recruit patient immune effector functions to destroy the 
marked target. The antibody dependent cellular cytotoxicity (ADCC) is triggered by an 
interaction between the Fc region of an antibody bound to, for example, a tumor cell and the 
Fcγ receptors on immune effector cells, leading to elimination of the tumor cell by 
phagocytosis or lysis, depending on the type of mediating effector cell. Complement 
dependent cytotoxicity (CDC) is initiated by complement component C1q binding to the Fc 
region of the antibody, triggering activation of the complement that leads to cell death by 
phagocytosis, lysis or disruption of the cell membrane. The recruitment of these patient 
immune effector functions is thought to be essential in the therapeutic effect of several 
recombinant mAbs used in oncology; the binding of recombinant mAb to the antigen is a 
necessary but not always sufficient condition for therapeutic effect. Fc-dependent effector 
mechanisms are best achieved with antibodies of the IgG1 subclass. Monoclonal antibody can 
also be coupled to a chemotherapy agent or a radioactive isotope and so selectively deliver 
chemo- or radiotherapy to a cancer cell while avoiding healthy cells (Nieri et al., 2009). 
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Fig. 1: Engineering of monoclonal antibodies. 
Schematic representation of mouse, chimeric, humanized and human IgG monoclonal antibodies. Figure 
reproduced (Carter, 2001). 
 
Production of monoclonal antibodies was enabled by the hybridoma technology developed by 
Köhler and Milstein in 1975 (Kohler and Milstein, 2005). They fused a human myeloma cell 
(a cancerous immune B cell) that can no longer secrete antibodies to a normal B cell from a 
mouse that has been immunized to secrete a particular antibody. The result of this fusion is 
called hybridoma and it has the properties of multiplying indefinitely and producing one 
single type – thus monoclonal – of antibody. The first mAbs obtained by hybridoma 
technology turned out to have safety and efficacy problems (Carter, 2001). Due to their mouse 
origin, these mAbs are immunogenic to humans, have short in vivo half-lives and generally do 
not kill target cells efficiently because they fail to trigger the immune effector functions of 
antibody dependent cellular cytotoxicity (ADCC) and complement dependent cytotoxicity 
(CDC). The realization of the great therapeutic potential of monoclonal antibodies was only 
made possible by the advent of technologies designed to overcome the limitations of the first 
mouse monoclonal antibodies – Fig. 1. These technologies are, in historical order of 
development, the chimerization and humanization of murine antibodies, and direct routes to 
high-affinity human antibodies using phage display libraries or transgenic mice (Carter, 2001; 
Waldmann, 2003). Chimerization consists on joining the antigen binding variable domains of 
a mouse mAb to human constant domains (Morrison et al., 1984). Humanization implies 
grafting the appropriate complementarity-determining regions (CDRs) (responsible for the 
desired binding properties) into a human antibody framework (Jones et al., 1986). Human 
monoclonal antibodies can either be obtained from very large, single chain variable fragments 
or Fab phage display libraries (de Haard et al., 1999) or from hybridoma technology using 
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transgenic mice with human immunoglobulin genes (Lonberg, 2005). Chimeric, humanized 
and human antibodies have reduced immunogenicity resulting in improved pharmacokinetics 
and since the Fc regions can be recognized by the patient’s immune system, they are 
efficacious on recruiting effector functions to kill target cells. 
 
 
The generation of more specific and higher affinity mAbs with reduced immunogenicity have 
enabled antibody therapeutics to become a major weapon in the treatment of leukemia and 
lymphoma. The first anticancer mAb, Rituxan/rituximab, was approved in 1997 for the 
treatment of non-Hodgkin’s lymphoma. From the nine commercially available therapeutic 
mAbs approved by the FDA, five are being used for treatment of hematological malignancies 
and the other four for solid tumors (Table 1). 
 
Table 1: Antibodies approved by the FDA for cancer treatment. 
Antibody /Product name Target Type Indications 
Rituximab /Rituxan CD20 Chimeric B-cell lymphoma 
Trastuzumab /Herceptin HER2 Humanized  Breast cancer 
Gemtuzumab /Mylotarg CD33 Humanized; toxin-conjugate Acute myeloid leukemia 
Alemtuzumab /Campath CD52 Humanized Chronic lymphatic 
leukemia. 
90Y-ibritumomab /Zevalin CD20 Murine; radionuclide-conjugate B-cell lymphoma 
131I-tositumomab /Bexxar CD20 Murine; radionuclide-conjugate B-cell lymphoma 
Bevacizumab /Avastin VEGF Humanized Colorectal, breast and lung 
cancer 
Cetuximab /Erbitux EGFR Chimeric Colorectal and head and 
neck cancer 
Panitumumab /Vectibix EGFR Entirely human Colorectal cancer 
Sources: (Zhang et al., 2007b; Biotechnology Industry Organization, 2008) 
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3 2BEGFR-TARGETED ANTICANCER THERAPY 
3.1 11BIntroduction 
Classical anticancer therapy has been based on cytotoxic agents with steep dose-toxicity 
relationships that limited clinical dose and efficacy. In the last decade, exponential growth in 
knowledge about cancer has led to the development of agents targeted against the inherent 
basis of cancer. It is hoped that such therapeutics will result in greater specificity, less toxicity 
and higher therapeutic indices (Rowinsky et al., 2007). In order to develop such agents it is 
necessary to identify and understand the aberrant biochemical and molecular pathways that 
distinguish malignant from non-malignant cells. Cancer research of the past decades has 
provided definitive evidence that cancer is a genetic disease (Park and Vogelstein, 2003). The 
current view is that cancers arise through a multistage process in which inherited and somatic 
mutations of genes lead to selection of variant progeny with the most robust and aggressive 
growth properties. Two classes of genes, proto-oncogenes and tumor suppressor genes, have 
been identified as mutation targets. In general, proto-oncogenes have critical roles in growth 
regulatory pathways and mutation leads to an increased activation (Pierotti et al., 2003). 
Tumor suppressor genes, on the contrary, are defined by their inactivation in cancer (Park and 
Vogelstein, 2003). The epidermal growth factor receptor is one proto-oncogene; mutation or 
abnormal expression can convert it into an oncogene and may lead to oncogenic 
transformation of the cell. 
 
3.2 12BThe epidermal growth factor receptor 
The Epidermal Growth Factor Receptor (EGFR) is one of a family of four receptor tyrosine 
kinases known as the ErbB or HER receptors involved in critical cellular processes such as 
proliferation, differentiation and apoptosis (Schlessinger, 2000; Holbro and Hynes, 2004; 
Hubbard and Miller, 2007). The mature EGFR contains an extracellular ligand binding region, 
a transmembrane domain and an intracellular tyrosine kinase domain similar to other 
receptors from the ErbB family (Burgess et al., 2003). EGFR is regulated by at least seven 
distinct peptide ligands (Harris et al., 2003), including EGF, transforming growth factor- 
  EGFR-targeted anti-cancer therapy 
8 
(TGF-), amphiregulin, betacellulin, epigen, epiregulin, and heparin binding EGF-like growth 
factor (HB-EGF). It is widely accepted that ligand binding to EGFR shifts a monomer-dimer 
equilibrium favouring receptor dimerization (Zhang et al., 2006; Lemmon, 2009). Receptor 
dimerization brings the intracellular tyrosine kinase domains into close proximity resulting in 
activation of the kinase domain through an allosteric mechanism. Intracellular kinase 
activation involves auto-transphosphorylation, which promotes the recruitment of downstream 
signalling proteins and subsequent modulation of a complex intracellular signalling network 
(Oda et al., 2005). It is also thought that EGFR can form an array of heterodimers with other 
ErbB receptors, thus increasing the complexity of signalling by this family (Yarden and 
Sliwkowski, 2001).  
 
 
Fig. 2: Cartoon representation of EGF-induced dimerization of the EGFR extracellular region. 
The unliganded state of the EGFR extracellular region adopts a tethered configuration (left).  EGF binding to this 
structure is accompanied by a conformational change that can be modelled approximately by a 130° rotation of 
the domain I/II fragment about the axis between domains II and III (Burgess et al., 2003). This change causes 
EGFR to adopt an extended conformation, in which EGF binding to both domains I and III is allowed and the 
dimerization arm in domain II is exposed. The extended EGFR molecule dimerizes through domain II-mediated 
interactions, with possible additional contributions from domain IV. Conceptual structural intermediates are 
shown: (i) an extended, unliganded monomer and (ii) an extended ligand-bound monomer. Crystal structures 
have been observed of the tethered monomer (Ferguson et al., 2003) and ligand-induced dimers (Ogiso et al., 
2002; Garrett et al., 2002). Figure reproduced and adapted (Schmitz and Ferguson, 2009). 
 
Based on x-ray crystal structures solved for EGFR extracellular regions in the absence 
(Ferguson et al., 2003) and presence (Ogiso et al., 2002; Garrett et al., 2002) of ligand, a 
model for ligand dependent dimerization and activation of EGFR has been proposed (Burgess 
et al., 2003) (Fig. 2). In the unliganded state the receptor adopts a tethered conformation 
characterized by an intramolecular interaction between domain II and domain IV (Ferguson et 
al., 2003) (left hand in Fig. 2). This conformation is thought to be autoinhibited (Burgess et 
al., 2003). Ligand binding to both domains I and III stabilizes an extended conformation of 
EGFR where dimerization interfaces on domain II and IV are exposed. Ligand binding is thus 
linked to a dramatic conformational change that is involved in receptor dimerization. In 
contrast to other receptor tyrosine kinases, EGFR dimerization is entirely receptor mediated 
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(Ogiso et al., 2002; Garrett et al., 2002). The majority of interactions in the dimer of the 
EGFR extracellular domains is contributed by a region in domain II that has been called 
‘dimerization arm’ (Ogiso et al., 2002). Further interactions in the extracellular EGFR dimer 
are contributed by parts of domain IV that are close to or contacting each other as suggested 
by modeled structures (Ferguson et al., 2003) and biochemical and biophysical data (Berezov 
et al., 2002; Dawson et al., 2007). 
 
The model for ligand-dependent EGFR dimerization presented in Fig. 2 is a simplification of 
a complex equilibrium of EGF binding to EGFR and receptor homo- and hetero-dimerization 
on the cell surface (Lemmon, 2009). Various reports have suggested negative cooperativity in 
EGF binding to EGFR and the existence of pre-formed EGFR dimers (Wofsy et al., 1992; 
Macdonald and Pike, 2008). Furthermore, it is thought that the transmembrane and 
intracellular domains also contribute to trigger dimerization and could be crucial for 
regulating the association of two EGFR.  
 
3.3 13BEGFR and cancer 
EGFR has been an oncology target for over 20 years. It was the first cell-surface receptor to 
be linked directly to cancer, as described in fibroblasts infected with oncogenic viruses (De 
Larco and Todaro, 1987). This report followed seminal observations about growth factors (De 
Larco and Todaro, 1978) and the elaboration of the theory of autocrine secretion (Sporn and 
Roberts, 1985): cancer cells generally exhibit a reduced requirement for exogenously supplied 
growth factors to maintain a high rate of proliferation. EGFR signalling can activate 
proliferation, protection from apoptosis, loss of differentiation, migration and invasion – all 
known hallmarks of cancer. It is now known that EGFR is aberrantly activated in a variety of 
epithelial tumors (Mendelsohn and Baselga, 2006). Mechanisms leading to aberrant receptor 
activation include receptor overexpression, gene amplification, activating mutations, 
overexpression of associated ligands and/or loss of negative regulatory controls (Mendelsohn 
and Baselga, 2006; West et al., 2008). Moreover, increased EGFR expression has been 
correlated to poorer clinical outcome for patients (Normanno et al., 2006). The type III EGFR 
mutation (EGFRvIII) is the most common EGFR mutation and clinically connected with 
cancer. It is a truncated version of the wild type EGFR showing constitutive signaling activity 
and impaired down-regulation (Pedersen et al., 2001). Structurally, EGFRvIII is characterized 
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by unaltered domains III and IV while nearly the whole of domains I and II are missing in 
comparison to full length EGFR. 
 
There are two classes of therapeutics targeting EGFR: low molecular weight tyrosine kinase 
inhibitors and monoclonal antibodies. Tyrosine kinase inhibitors act on the protein kinase 
domain of the receptor by either competing with ATP or modifying the ATP binding pocket 
so that receptor phosphorylation is inhibited. They are somewhat promiscuous in their 
specificity for the target and usually inhibit other tyrosine kinases to varying degrees. 
Although in general a disadvantage, such low specificity can be of clinical benefit, as tumor 
cells usually contain several ErbB family members and heterodimerization occurs routinely 
(Zhang et al., 2007a). 
 
Table 2: EGFR overexpression in tumors.  
Tumor type Percentage of tumors 
overexpressing EGFR 
Colon 25-77% 
Head and neck 80-100% 
Pancreatic 30-50% 
Non-small cell lung 40-80% 
Breast 14-91% 
Source: (Herbst and Shin, 2002) 
 
3.4 14BAnti-EGFR monoclonal antibodies  
Effective inhibition of EGFR signalling by mAbs has been  related to several modes of action: 
direct steric blockage of ligand binding or receptor dimerization, stabilization of the tethered 
conformation, block of the domain rearrangement required for receptor dimerization, 
antibody-dependent cellular cytotoxicity (ADCC) and complement dependent cytotoxicity 
(CDC), antibody-mediated receptor down-regulation and augmentation of the antitumor 
effects of chemo- and radiotherapy (Mendelsohn and Baselga, 2006; Leahy, 2008; Schmitz 
and Ferguson, 2009). 
 
Examples of anti-EGFR monoclonal antibodies already approved or that have made it all the 
way to clinical trials are given below. 
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Cetuximab/Erbitux. A chimeric modification of the antibody 225, the latter originally 
obtained by inoculation of mice with EGFR and hybridoma technology by Prof. 
Mendelsohn (University of Texas M.D. Anderson Cancer Center) (Sato et al., 1983). 
The chimeric version was developed by ImClone Systems and has been approved by the 
FDA (2004), the EU (2004) and Japan (2008) for treatment of patients with colorectal 
and head and neck cancer. The approval covers the application in combination with 
chemo- or radiotherapy or as a single agent in patients who have failed those therapies. 
Erbitux is manufactured and distributed by ImClone and Bristol-Myers Squibb in North 
America and by Merck KGaA in the rest of the world.  
 
Panitumumab/Vectibix. A fully human antibody of the IgG2 type derived from the 
immunization of transgenic mice that express fully human antibodies (Yang et al., 
2001). Initially developed by Abgenix, it is nowadays developed and commercialized 
by Amgen. It has been approved by the FDA (2006) and EU (2007) for the treatment of 
patients with colorectal cancer in combination with chemotherapy or as monotherapy 
after failure of chemotherapy regimens. 
 
Nimotuzumab/Theracim. A humanized antibody developed at the Centre of Molecular 
Immunology in Havana (Fernandez et al., 1992; Mateo et al., 1997). It has limited 
nation approval for the treatment of head and neck cancer and glyoma and is 
commercialized by YM Biosciences and its licensees. 
 
Zalutumumab. A fully human monoclonal antibody developed by GenMab using 
transgenic mice (Bleeker et al., 2004). It is in advanced clinical testing. 
 
Matuzumab/EMD72000. The humanized form of the murine mAb 425 developed at 
the Wistar Institute, in Philadelphia (Murthy et al., 1987). Development is driven by 
Merck KGaA and Phase I data is available. 
 
IMC-11F8. A fully human antibody constructed using an isolate from a non-immunized 
human Fab display library (Lu et al., 2004). Development is driven by Imclone and 
Phase I data is available. 
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c806. A chimeric version of mAb 806, derived from mice immunized with fibroblasts 
expressing EGFR variant III, but also binds to overexpressed wild-type EGFR 
(Mishima et al., 2001). EGFRvIII is the most common gene disruption of the 
extracellular region of EGFR, and is found in about 25% of glioblastomas, as well as in 
a number of solid tumors (Kuan et al., 2001). c806 is in Phase I trials. 
 
Anti-EGFR mAbs interact with the extracellular region of EGFR and interfere with EGFR 
signalling by different mechanisms, as revealed by structural studies (Peipp et al., 2008). 
Mechanisms of EGFR antagonist by mAbs include i) stabilization of tethered conformation, 
ii) block of domain rearrangement required to attain the extended state, iii) direct block of 
ligand binding and iv) direct block of receptor dimerization. 
 
 
 
Fig. 3: EGFR inhibition by antibodies. 
(A) Antibody binding directly occludes the ligand-binding 
site – this mode of inhibition is important for cetuximab, 
IMC-11F8, panitumumab and zalutumumab (Rich and 
Myszka, 2007b; Rich and Myszka, 2008). (B) Antibody 
sterically prevents the receptor from adopting the 
conformation required for high affinity ligand binding and 
dimerization, without directly occluding a ligand-binding 
site. This mode is observed for matuzumab. Figure 
reproduced and adapted (Schmitz and Ferguson, 2009). 
 
 
Cetuximab (Fan et al., 1994; Li et al., 2005), panitumumab (Freeman et al., 2008), 
zalutumumab (Lammerts van Bueren et al., 2008) and IMC-11F8 (Li et al., 2008) interact 
with epitopes on domain III of EGFR that overlap with the EGF binding site on that domain, 
thus competing with EGF binding to the receptor). These antibodies inhibit EGFR primarily 
by directly blocking the ligand-binding site (Fig. 3A). Additionally, they sterically prevent the 
receptor from adopting the extended dimerization-capable conformation and they eventually 
stabilize the tethered conformation. Nimotuzumab also binds to an epitope situated in domain 
III, overlapping with the ligand binding site, thus blocking ligand binding. However, 
differently from the other mAbs, nimotuzumab binding to EGFR seems to be compatible with 
the active extended receptor conformation (Talavera et al., 2009). Matuzumab interacts with 
an epitope situated on domain III of EGFR, not overlapping with the ligand-binding site. 
Ligand binding is not directly blocked (Fig. 3B); instead matuzumab sterically prevents the 
receptor from adopting the conformation required for high affinity ligand binding and 
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receptor dimerization (Schmiedel et al., 2008). An altogether different inhibition mechanism 
is followed by c806, which binds to an epitope in domain II near the dimerization domain that 
does not seem to be available in either tethered or extended conformation (Johns et al., 2004; 
Sivasubramanian et al., 2006). Thus, it is believed that c806 binds to an intermediary EGFR 
conformation, directly blocking receptor dimerization. 
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4 3B IOPHYSICAL CHARACTERIZATION OF 
ANTIBODY-RECEPTOR INTERACTIONS 
4.1 15BIntroduction 
Binding specificities of monoclonal antibodies against virtually any antigen can be generated 
whether by conventional hybridoma technology or with antibody libraries displayed on 
filamentous phage or other display systems. The determination of antibody-antigen interaction 
properties is key to understand antibody performance in therapeutic applications. Scientists 
aim to understand the mechanisms of antibody-antigen interactions, their energetic and 
dynamic properties as well as structure-function relationships. Biophysical tools help 
providing a quantitative basis together with a highly resolved definition in terms of assembly 
state, epitope and/or allostery mapping, affinity, kinetics and thermodynamics of complex 
formation (Bergethon, 1998). Focus of this thesis was the biophysical characterization of the 
interactions between EGFR and four therapeutic monoclonal antibodies. Interactions of the 
receptor with two natural agonists were also studied. In this chapter, an introduction to the 
physical properties that characterize an interaction and the innovative biophysical tools used – 
surface plasmon resonance, isothermal titration calorimetry and static light scattering – will be 
given. 
 
4.2 16BPhysical properties of molecular interactions 
One of the most fundamental ways to quantitatively characterize the interaction between 
antibody (mAb) and receptor (Rec) as defined in Eq. 1 is to determine the binding affinity, or 
equilibrium dissociation constant (KD). KD is defined as the ratio of the rate constants 
(kinetic) or the ratio of concentrations at equilibrium, when ka is equal to kd, for a two-phase 
reversible interaction as defined in Eq. 2.  
 
ka (M-1s-1)
kd (s-1)
cRemAb + cRemAb⋅
 
Eq. 1 
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kK =  Eq. 2 
 
Affinity measurements give quantitative meaning to phrases such as tight binding and weak 
interaction, and refer to the stability of the bimolecular complex. Most often, bimolecular 
interactions are dynamic processes that occur in solution and include multiple association and 
dissociation phases. The smaller the dissociation constant, the more tightly bound the 
complex RecmAb ⋅  is, i.e. the higher the affinity of the complex. The dissociation constant is 
also of great practical utility for determining the protein concentration at which a complex 
might be formed.  
 
The study of protein-protein interactions in terms of the rates of association and dissociation 
is called kinetics. For the above given example, the rate at which the complex is formed is 
given by the product of the molar concentrations of mAb and Rec and the association rate 
constant, ka (Eq. 3). The association rate is a measure of the speed of recognition of two 
interactants in solution. It is thus dependent on the concentration of the interactants. Similarly, 
the rate at which the complex dissociates is the product of the molar concentration of complex 
RecmAb ⋅  and the dissociation rate constant, kd (Eq. 4). The dissociation rate is a measure of 
the instability of a complex; the higher the dissociation rate, the less stable is the complex. It 
is independent from the interactants concentration in solution. 
 
forward [ ] [ ][ ]cRemAbk
dt
cRemAbd
a=
⋅
 Eq. 3 
reverse
[ ] [ ]cRemAbk
dt
cRemAbd
d ⋅=
⋅
 Eq. 4 
 
The rate constants ka and kd are physical parameters that are fixed for a given pair of 
interactants under given conditions of temperature and solution environment - they are 
characteristics of the interaction process. Association and dissociation rates of antibody 
interaction vary by several orders of magnitude. Kinetics of antibody-antigen is commonly 
temperature dependent, which may be indicative of the structural plasticity involved in 
antigen binding – not rigid body-like. This plasticity is more common for small antigens. 
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Thermodynamically, the affinity is defined by the free energy difference between the 
associated and dissociated states of the proteins and surrounding solvent. At equilibrium, the 
Gibbs free energy change, ∆G, relates with the equilibrium dissociation constant (KD) by Eq. 
5, where R is the gas constant and T is the absolute temperature. 
 
DKRTG ln =  Eq. 5 
 
However, the free energy change of complex formation is only one part of the 
thermodynamics. Dissection of binding forces into enthalpic (∆H) and entropic (∆S) 
contributions provide useful information about the importance of various factors involved in 
the association and complements structure and kinetic information by providing a more 
complete understanding of the forces that lead to complex formation (Jelesarov et al., 1996; 
Jelesarov and Bosshard, 1999; Perozzo et al., 2004). The enthalpy and entropy change relate 
to the Gibbs free energy change by the Gibbs  equation shown in Eq. 6 (Williams et al., 
2004). 
 
STHG  −=  Eq. 6 
 
The Gibbs equation states that ∆G is negative for a spontaneous change. The enthalpy term is 
related to the strength of polar interactions (H-bonds, van der Waals) that take place in the 
complex and in the interactants alone. ∆H magnitude is related to geometry and strength of 
protein-protein and/or protein-solvent polar interactions; ∆H signal depends upon whether 
there is a net gain (negative) or loss (positive) of polar interactions (Velazquez-Campoy et al., 
2001; Holdgate, 2001). ∆H is negative if the process is exothermic and is positive if the 
process is endothermic. The entropy term is related to conformational and dynamic 
phenomena involving the proteins and the solvent. Favourable (positive) entropy changes are 
often associated with the release of water molecules from a binding interface whereas 
unfavourable (negative) entropy values are often linked to conformational or dynamic 
restrictions (Ward and Holdgate, 2001; Kwong et al., 2002).  
 
The ∆H of a reaction can, in general, be determined in one of two ways; it can be determined 
directly using calorimetry of indirectly by measuring the temperature dependence of the 
equilibrium constant. The latter is known as the van’t Hoff method. Substituting Eq. 5 in Eq. 
6 gives the van’t Hoff relation in Eq. 7. 
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STHKRT D ln −=    or   R
S
TR
HKD
1ln −⋅=  Eq. 7 
 
The plot of ln KD against 1/T is a straight line, with slope ∆H/R and intercept on the y-axis 
∆S/R. This simplified relationship does not hold if the heat capacities of reagents and products 
differ, i.e. if ∆H and ∆S are not constant with the temperature. In such cases, the plot of ln KD 
against 1/T is not linear and the relationship becomes  
 
( ) 





−−+−=
0
0 lnln 00 T
TCTTTCSTHKRT PPTTD  Eq. 8 
 
where T0 is the reference temperature (25°C for standard conditions). A non-linear fitting of 
the data to this extended equation yields in addition to ∆H and ∆S a value for the standard 
heat capacity change ∆CP, that stands for the temperature dependence of the enthalpy change. 
 
4.3 17BSurface plasmon resonance 
The use of surface plasmon resonance for biosensing purposes was first demonstrated by 
Liedberg in 1983 (Liedberg et al., 1983), making use of the Kretschmann method for 
excitation of surface plasmons (Kretschmann, 1971). In 1990, Pharmacia Biosensor launched 
Biacore (Liedberg et al., 1995), the first and until today most commonly used SPR-based 
technology for characterization of real-time biomolecular interactions (Ernst et al., 2009). 
SPR detection allows direct measure of the binding of a molecule in solution to a surface 
immobilized binding partner and determine both the kinetics of that interaction, association 
(ka) and dissociation rates (kd), and the affinity (equilibrium dissociation constant, KD). SPR-
based biosensors are nowadays an established method for the real-time label-free analysis of 
molecular interactions (Morton and Myszka, 1998; Rich and Myszka, 2006; Rich and 
Myszka, 2007b; Rich and Myszka, 2008)). The advantages of these technologies include no 
labelling of the molecules and small sample volumes. The majority of the work published in 
the antibody field originates from real time binding analysis based on biosensor instruments 
produced by Biacore (GE Healthcare), although several other instrumentation manufacturers 
have entered the field (Rich and Myszka, 2007a). 
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Fig. 4: An example of a sensorgram. 
Real time information about the antibody antigen interaction is observed. The association and dissociation 
phases are measured in resonance or response units (RU) as a function of time. 
 
The basic diagram of biosensor output is called sensorgram (Fig. 4). The change in the 
detected SPR signal is expressed as resonance/response units, or RU, and is followed as a 
function of time. The response detected has been shown to be proportional to the mass bound 
or deposited at the surface (Stenberg et al., 1991). The sensorgram in Fig. 4 outlines the five 
basic phases during the binding of an antigen to an immobilized antibody or vice-versa. The 
first phase is the baseline signal or the pre-injection phase of buffer only, which is followed 
by the injection of analyte and consequent association phase. Once the injection is stopped, 
the association phase ends. Then, the analyte solution is replaced with buffer and the 
dissociation phase begins, which monitors the dissociation of the analyte from the 
immobilized ligand or the dissociation of the complex over time. The final phases are for the 
regeneration of the sensor surface, to remove all bound analyte using predetermined 
regeneration reagents and conditions, followed by a stabilization phase where only buffer is 
flowing and maintaining the surface in preparation for the next round of analyte injection. In a 
typical kinetic experiment, a set of varying concentrations of one binding partner is injected 
sequentially onto the surface where the other binding partner has been immobilized. The 
kinetic data analysis is done by curve fitting calculations. The simplest model for kinetic 
evaluation is the 1:1 binding model, describing a binary interaction, where one analyte species 
interacts with one ligand at a single uniquely defined site. This model is recommended for 
data treatment as default unless there is good experimental reason to choose a different model. 
Other more complicated binding models include heterogeneous ligand model, where bound 
interactant may be present in multiple forms, bivalent and heterogeneous analyte models 
(Karlsson et al., 1994; Karlsson and Falt, 1997; Alfthan, 1998). The use of these alternative 
models requires previous knowledge of such interactions that deviate from 1:1 interaction.  
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Surface plasmon resonance biosensing is based on measures of refractive index change 
occurring as molecules adsorb to or dissipate from a sensor surface during reaction (Huber 
and Mueller, 2006). If light of an appropriate wavelength is directed upon the metal/prism 
interface at an incident angle within certain narrow limits, the delocalised surface electrons of 
the metal at the metal/external medium interface are resonantly excited into a collective 
motion, termed a ‘plasmon’. Energy is thus transferred from the light beam to the surface 
electrons, resulting in a decrease in the intensity of the reflected beam (Liedberg et al., 1995). 
The angle at which incident light excites the surface plasmon is extremely sensitive to the 
refractive index of the medium adjacent to the metal surface. Thus, either the binding or 
dissociation of proteins to the surface perturbs the local refractive index and produces a 
change in the angle at which incident light must strike the interface to produce a minimum in 
the intensity of the measured reflected light (Fig. 5). The energy that is transferred from the 
light beam to the surface electrons has been called evanescent wave. Intensity of the optical 
fields in this surface wave decays exponentially with distance from the surface over about 100 
nm, and the value of the SPR angle is therefore very sensitive to the refractive index of the 
medium adjacent to the surface. 
 
Y     Y    Y            Y     Y    Y   
Flow channel
Prism
Sensor surface
with gold film
Polarized
light I II
 
Fig. 5: The surface plasmon resonance detection.  
In Biacore systems, the incident p-polarized light is focused into a wedge-shaped beam providing simultaneously 
a continuous interval of light wavevectors kx. This range covers the working range for the plasmon wavevector 
ksp during biomolecular interaction analysis. An increased sample concentration in the surface coating of the 
sensor chip causes a corresponding increase in refractive index which alters the angle of incidence required to 
create the SPR phenomenon (the SPR angle). This SPR angle is monitored as a change in the detector position 
for the reflected intensity dip (from I to II). By monitoring the SPR-angle as a function of time the kinetic events 
in the surface are displayed in a sensorgram. (Biacore, 1998) 
 
Biacore systems typically use a carboxymethylated dextran layer on the surface of a gold chip 
for biomolecular interactions. The dextran layer, about 100 nm thick, utilizes the evanescent 
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field in an efficient way and provides for a hydrophilic and freely mobile environment for the 
interaction to take place, as it contains 97 to 98% water. Furthermore, it provides the surface 
with the carboxyl groups to which biomolecules can be coupled using known techniques 
(Jonsson et al., 1991). Immobilization of biomolecules to the sensor chip surface can be done 
by covalent immobilization, high affinity capture or hydrophobic adsorption. Immobilization 
via amine groups is the most popular method used for surface immobilization. The coupling 
normally occurs between the primary amine group of lysine residues at the surface of the 
protein and the free carboxylic acid groups on the surface of the sensor chip which are 
generated by treatment with 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC) and N-
hydroxysuccinimide (NHS). The preparation of a surface that can be regenerated for multiple 
cycles of analysis is crucial for kinetic analysis using a series of analyte concentrations 
(Biacore, 2008). 
 
The establishment of commercial biosensors and concretely Biacore technology was due to 
the development of automated liquid handling capacity with the integrated fluid control unit 
(Liedberg et al., 1995). The integrated microfluidic cartridge contains sample and buffer loops 
and provides for very efficient and accurate sample delivery that is important for assay 
reproducibility and provides the controlled conditions necessary for kinetic studies (Sjolander 
and Urbaniczky, 1991). The microfluidic cartridge is pressed against the sensor chip to form 
the flow cells, where the interaction takes place. 
 
4.4 18BIsothermal titration calorimetry 
Isothermal titration calorimetry (ITC) is the only technique that directly measures the 
enthalpy change upon binding (Holdgate and Ward, 2005). The technology is well established 
in drug discovery and has proven applicability for the study of antibody-receptor interactions 
(Jelesarov et al., 1996). ITC analysis is based on the direct measurement of the heat absorbed 
or released upon interaction. Most ITC instruments operate a differential cell feedback system 
(Pierce et al., 1999; Holdgate and Ward, 2005), as shown in Fig. 6. A pair of identical coin 
shaped cells is enclosed in an adiabatic outer shield: a reference cell, filled with water or 
buffer; and a sample cell containing a solution of one interactant. Injection of the other 
interactant into the sample cell produces heat effects that arise from three sources: the binding 
interaction, dilution of the interactants and mixing. The heat changes arising in the sample cell 
cause a temperature difference between the two cells, which is detected by the calorimeter and 
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triggers a change in the feedback power applied to maintain temperature equilibrium. A 
reaction which results in the evolution of heat within the sample cell (exothermic) causes a 
negative change in the feedback power since the heat evolved chemically provides heat that 
the feedback power is no longer required to provide (see example titration in Fig. 6). The 
opposite is true for endothermic reactions.  
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Fig. 6: Typical isothermal titration calorimetry instrument and data. 
 
In Fig. 6 is shown a schematic illustration of an example ITC experiment where antibody is 
titrated to receptor. On the right side of the picture, the raw data resulting from the titration 
and the typical titration sigmoidal curve resulting from integration of the raw data are 
presented. Each peak in µcal/sec vs. time corresponds to the heat released on addition of an 
aliquot of antibody to the receptor. Integration of the differential power signal with respect to 
time yields the apparent heat change between two consecutive antibody additions, that 
corresponds to the area of the peak. If the association constant (KA=1/KD) is large and the 
molar ratio of antibody to receptor at the beginning of the titration is low, then virtually all the 
antibody is bound to the receptor and the peak areas are similar, giving a measure of the 
binding enthalpy (∆H). As the fractional saturation increases, the apparent heat change 
gradually decreases. This part of the titration allows estimation of the association constant 
(KA) and stoichiometry (N) of the binding. Eventually, all receptor sites are saturated. Small 
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heat changes registered after full saturation are caused by the heat of antibody dilution or by 
other non-specific effects. A non-linear regression to the procedure yields stoichiometry, 
association constant and binding enthalpy from one single titration experiment. 
 
The enthalpy change measured by ITC is a global property of the system. It is the total heat 
released or absorbed in the calorimetric cell on each addition of the antibody. The total heat 
contains contributions arising from non-specific effects, such as dilution, mixing of buffers 
with slightly different compositions or incomplete match of the temperatures of the solutions 
in the cell and at the injection syringe. Unspecific contributions to the enthalpy of binding 
arising from unmatched buffer compositions in the cell and in the syringe can be avoided 
through dialysis of samples in the same buffer.  
 
Modern ITC instruments allow to precisely measure enthalpies in a wide temperature range 
and from the temperature dependence of enthalpy, the heat capacity change (∆CP) can be 
calculated.  
 
4.5 19BStatic light scattering 
When light impinges on a macromolecule, the oscillating electric field of the light induces an 
oscillating dipole within the molecule. Light is thus re-radiated with an intensity that depends 
on the magnitude of the dipole induced within the macromolecule. The more polarizable the 
macromolecule is, the larger the induced dipole, and hence, the greater the intensity of the 
scattered light. Analysis of the intensity of light scattered by a solution can provide 
information about the native molecular weight, oligomeric composition and conformation of 
the molecules present in solution. The theory of light scattering was developed by some of the 
greatest scientists of the twentieth century; among them Einstein, Lord Rayleigh, Raman and 
Debye. Although the theory of light scattering dates back to the nineteenth century, routine 
use of light scattering techniques was linked to the commercial availability of stable lasers as 
light sources (Demeester et al., 2005).  
 
Static light scattering is based on the principle of analyzing the time-averaged intensity of 
light scattered by a solution. Static light scattering methods are based on the Debye-Zimm 
equation, shown in Eq. 9 (Harding and Jumel, 2001). 
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 Eq. 9 
 
Where A2 is the thermodynamic nonideality coefficient, Rθ is the Rayleigh excess ratio (the 
ratio of the intensity of excess light scattered compared to pure solvent) at a scattering angle 
θ, K is an experimental constant dependent on the square of the solvent refractive index, the 
square of the refractive index increment (dn/dc) and the inverse fourth power of the incident 
wavelength, M is the molecular weight, c is the solute concentration and P(θ) is the form 
factor. 
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Fig. 7: Schematic representation of typical light scattering method for analysis of antibody-receptor 
interactions. 
 
In this study, a multi-angle light scattering detector was employed, in combination with size 
exclusion chromatography and a refractive index detector – Fig. 7. Multi-angle light 
scattering (MALS) analysis involves performing light scattering measurements at different 
angles with the advantage of higher precision in the determination of molecular weights in 
comparison to single angle methods (Harding and Jumel, 2001). The coupling of MALS 
photometers to size exclusion chromatography systems has been a revolutionary development 
since it allowed fractionation of polydisperse materials prior to scattering analysis (Wyatt, 
1993). MALS analysis of the chromatographically separated fractions provides information 
on the molecular weight distribution of proteins or protein complexes provided an additional 
concentration detector is present. Typically, a refractive index (RI) or UV detector is 
employed. An important feature of the RI detector is that it requires no knowledge of the 
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extinction coefficient of the proteins for data analysis. For a protein, or protein complex, that 
does not contain carbohydrates, the refractive index increment, dn/dc – where n is the 
refractive index and c is the protein concentration – is constant and nearly independent of its 
amino acid composition. Combining protein concentration from RI (or UV) detection with 
light scattering at different angles (normalized to the calibrated 90° detector), absolute 
measurement of molecular weight of proteins eluting from SEC can be performed. This 
technology has already been applied for the analysis of antibody-antigen mixtures in 
stoichiometry studies (Qian et al., 1997; Arakawa and Wen, 2001; Rehder et al., 2008).  
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5 4BMATERIALS AND METHODS 
5.1 20B uffer 
The buffer PBS with 3mM EDTA, 0.05% (v/v) Tween 20 pH 7.4 will be further referred to as 
PBS-EP+. 
 
5.2 21BProteins 
UEGFR 
A truncated soluble form of EGFR, excreted by A431 cells and consisting in almost the entire 
external domain was used for this work (Weber et al., 1984; Ullrich et al., 1984). It was 
obtained from PD Dr. Wolfgang Weber (UKE, Hamburg, Germany). EGFR stock solution 
was 2mg/ml and it was stored in aliquots at -70°C. 
 
The deletion mutant EGFR variant III (EGFRvIII) was a most kind donation from Dr. Judith 
Schmiedel (Merck KGaA). 
 
UAnti-EGFR antibodies 
The antibodies matuzumab and cetuximab were provided by Merck KGaA. The antibodies 
panitumumab and nimotuzumab are commercially available. An independent nimotuzumab 
vial was a very kind donation from Christof Reusch (Merck KGaA). Antibody solutions were 
5 to 20 mg/ml and were stored at 4°C. 
 
UFab fragments preparation 
The antibodies matuzumab were enzymatically cleaved by papain digestion to generate Fab 
fragments. The Fab fragments were further purified by protein A affinity chromatography. 
The Pierce Fab Preparation Kit from Thermo Scientific (Rockford, IL, USA) was used 
according to the manufacturer’s instructions. Antibody formulations of 7.5 mg yielded about 
2 mg pure Fab fragments. These purified Fab fragments were stored at 1 mg/ml at 4°C in 
PBS-EP+. 
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UEGFR ligands 
EGF was from US Biological (Swampscott, MS, USA). It was reconstituted in water to a 
concentration of 1 mg/ml in PBS and stored at -20°C. TGF-α was from Chemicon /Millipore 
(Billerica, MA, USA). It was directly reconstituted in PBS-EP+ to a concentration of 1 mg/ml 
and stored at -20°C. 
 
UOther proteins 
Protein A and Human Fab Binder for surface plasmon resonance biosensor immobilization 
were obtained from GE Healthcare Biosciences AB (Uppsala, Sweden). 
 
5.3 22BSurface plasmon resonance 
SPR studies were carried using a Biacore T100 from GE Healthcare (Uppsala, Sweden) 
(Biacore, 2005; Biacore, 2006). All experiments were done using PBS-EP+ as running and 
sample buffer. Biacore data was collected with Biacore T100 Control Software and analyzed 
using Biacore T100 Evaluation Software, both delivered with the instrument.  
 
5.3.1 35BProtein immobilization and regeneration conditions 
All proteins were immobilized onto Biacore CM5-chips from GE Healthcare (Uppsala, 
Sweden) as follows: the CM-dextran matrix was activated with N-ethyl-N’- 
(dimethylaminopropyl)-carbodiimide hydrochloride (EDC) and N-hydroxysuccinimide 
(NHS). After protein immobilization the remaining reactive sites were blocked with 1 M 
ethanolamine-HCl (pH 8.5). Immobilization, capture and regeneration were performed at a 
flow rate of 10 µl/min. 
 
UProtein A surface 
Protein A (100 g/ml) was immobilized in 10 mM sodium acetate (pH 4.5) for 7 min with a 
final immobilization level of 4800 response units (RU). Antibodies matuzumab, cetuximab 
and panitumumab (0.5 µg/ml) were captured onto protein A surface for 30 s with capture 
levels of 60 RU. Nimotuzumab (0.5 µg/ml) was captured for 60 s with a capture level of 60 
RU. Protein A surfaces were regenerated with a 30 s pulse of 10 mM glycine (pH 1.7). 
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UHuman Fab Binder surface 
The Biacore Human Fab Capture Kit from GE Healthcare (Rockford, IL, USA) was used 
according to the manufacturer’s instructions. Human Fab binder (20 µg/ml) was immobilized 
for 7 min with a final immobilization level of 14000 RU. Fab fragments of the antibodies 
matuzumab, and nimotuzumab (0.5 µg/ml) were captured onto Human Fab Binder surface for 
30 s with capture levels of 30 RU. Fab fragments of panitumumab was captured for 42 s with 
capture levels of 30 RU. Human Fab Binder surfaces were regenerated with a 60 s pulse of 10 
mM glycine (pH 2.1). 
 
UAntibody/Fab fragment surface 
For kinetic studies, all four mAbs (1 µg/ml) were immobilized in 10 mM sodium acetate (pH 
5.0). Matuzumab was immobilized for 100 s with a bound immobilization of 280 RU. 
Cetuximab was immobilized for 80 s with a bound immobilization of 180 RU. Panitumumab 
was immobilized for 80 s with a bound immobilization of 140 RU. Nimotuzumab was 
immobilized for 120 s with a bound immobilization of 380 RU. Fab fragments were 
immobilized in 10 mM sodium acetate (pH 5.0). Matuzumab, cetuximab and panitumumab 
Fab fragments (1µg/ml) were immobilized for 120 s with a bound immobilization of 250 RU, 
40 RU and 30 RU respectively. Nimotuzumab Fab fragment (8µg/ml) was immobilized for 
120 s with a bound immobilization of 860 RU. 
 
For studies of interdependence of antibody binding, the flow rate and immobilization buffer 
were maintained but concentration and contact time were increased to 25 µg/ml and 7 min 
respectively. Matuzumab, cetuximab, panitumumab and nimotuzumab yielded final 
immobilization levels of 17,500, 15,000, 12,000 and 18,000 RU, respectively. EGFR 
(3µg/ml) was then captured by these surfaces through 40 s – in matuzumab or nimotuzumab – 
or 60 s injections – in cetuximab or panitumumab surfaces. EGFR capture levels were 360, 
820, 700, 300 RU, for matuzumab, cetuximab, panitumumab and nimotuzumab respectively. 
 
Antibody and Fab fragment surfaces were regenerated with a 15 s pulse of 10 mM NaOH and 
1 M NaCl. 
 
UmAb-EGFR crosslinked surface 
Matuzumab, cetuximab, panitumumab and nimotuzumab were immobilized as described 
above for studies of interdependence of antibody binding. Subsequently, EGFR (100 µg/ml) 
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was injected for 120 s onto matuzumab, cetuximab and panitumumab surfaces. As for 
nimotuzumab surface, EGFR (33 µg/ml) was injected for 120 s. EGFR capture was followed 
by a 120 s long injection of EDC/NHS and a 120 s long injection of ethanolamine for 
crosslinking of EGFR to the immobilized mAbs. Crosslinked EGFR yielded 750, 4000, 4700 
and 600 RU for matuzumab, cetuximab and panitumumab surfaces respectively. 
 
UEGFR surface 
For EGF/TGF-α titrations, EGFR (5 µg/ml) was immobilized in 10 mM sodium acetate (pH 
5.0) for 6.7 min with a final immobilization level of 3000 RU. For Fab fragment titrations, 
EGFR (1.7 µg/ml) was immobilized in 10 mM sodium acetate (pH 5.0) for 6.7 min with a 
final immobilization level of 470 RU. EGFR surfaces were regenerated with a 15 s pulse of 
10 mM NaOH and 1 M NaCl. 
 
UEGF surface 
EGF (50µg/ml) was immobilized in 10 mM sodium acetate (pH 4.0) for 40 s with a final 
immobilization level of 100 RU. EGF surface were regenerated with a 15 s pulse of 10mM 
NaOH and 1M NaCl. 
 
5.3.2 36BTitration and competition experiments 
For antibody/EGFR kinetic studies, EGFR was flown as twofold serial dilutions covering a 
concentration range 1.6 - 800 nM over the matuzumab, cetuximab, panitumumab and 
nimotuzumab antibodies either captured by protein A or directly immobilized. For Fab 
fragments/EGFR kinetic studies, the same EGFR concentrations were flown over directly 
immobilized Fab fragments. Alternatively, the Fab fragments were flown as twofold serial 
dilutions covering a concentration range 1.6 - 800 nM over directly immobilized EGFR. 
Nimotuzumab mAb/Fab kinetic experiments included one higher concentration point, 1600 
nM. For EGFRvIII binding studies, EGFRvIII was flown as twofold serial dilutions covering 
a concentration range 1.6 - 800 nM over cetuximab, panitumumab and nimotuzumab 
antibodies captured by protein A. All kinetic studies were performed at 40 µl/min with an 
association time of 100 s and a dissociation time of 200 s. 1:1 interaction models were fitted 
to binding curves. 
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For ligand/EGFR affinity experiments, EGF and TGF-α were flown as twofold serial 
dilutions covering concentration ranges 3.9 - 2000 nM and 7.8 - 4000 nM, respectively. These 
were injected at 30 µl/min for 30 s over EGFR surface. The dissociation time was 60 s. 
Steady state analysis was performed to the experimental results. 
 
Competition experiments were carried out with a constant concentration of the receptor 
protein (800 nM). The binding to a ligand surface was monitored while increasing amounts of 
antibodies ranging from 0-15 M were added to the receptor sample. 
 
5.3.3 37BVan’t Hoff analysis 
Van’t Hoff analysis was performed for matuzumab, cetuximab, panitumumab, nimotuzumab, 
EGF and TGF-α. EGFR was titrated onto antibody that has been captured by protein A. Other 
conditions used were the same as described in 5.3.2 and the analysis was repeated twice at 15, 
19, 22, 25, 31 37 and 40°C. Kinetic-originated antibody affinities and steady state-analysis 
ligand affinities were plotted ln KD vs. 1/T. The plots were all fitted with linear regression.  
 
5.3.4 38BAnalysis of maximal EGFR binding capacity on antibody surfaces 
Row-diluted concentrations 400, 800, 1600, and 3200 nM EGFR were titrated onto 
matuzumab and cetuximab mAbs. Row-diluted concentrations 400, 800, 1600, 3200 and 6400 
nM EGFR were titrated onto matuzumab and cetuximab Fab fragments. Row-diluted 
concentrations 400, 800, 1600, 3200, 6400 and 12800 nM EGFR were titrated onto 
nimotuzumab mAb and Fab fragments. mAbs were immobilized by protein A capture and 
Fabs were immobilized by Humab Fab binder capture. All experiments were repeated twice. 
 
5.3.5 39B inding interdependence of antibody combinations to EGFR 
Row-diluted concentrations 1.5, 3, 6, 12, 25, 50, 100, 200, 400, 800, 1600 and 3200 nM of 
antibodies matuzumab, cetuximab, panitumumab and nimotuzumab were titrated onto EGFR 
captured by immobilized antibodies or to EGFR crosslinked to immobilized antibodies. 
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5.4 23BIsothermal titration calorimetry 
All ITC measurements were performed with a VP-ITC microcalorimeter from Microcal, LLC 
(Northampton, MA, USA). Analysis buffer was PBS with 3 mM EDTA, 0.05% (v/v) Tween 
20 pH 7.4 and samples were previously dialysed at 4°C overnight against it. Data analysis 
was done using Origin 7 calorimetry software (MicroCal LLC). mAbs results were 
normalized to concentration of binding site. 
 
Simple titrations were performed as follows: Fab fragment (20 µM) or whole antibody (10 
µM) solutions were injected in 11 µl steps into the sample cell containing 2 ml EGFR (2 µM). 
Binding interdependence titrations were performed as follows: whole antibody (10 µM) 
solutions were injected in 11 µl steps into the sample cell containing 2 ml EGFR (2 µM) and a 
saturation concentration (such as 2 µM) of a second antibody. 
 
All binding experiments were carried out at 25°C with a spacing time between the injections 
of 320 s. 
 
Matuzumab/EGFR and cetuximab/EGFR titrations were repeated at 20°C and 33°C.  
 
UTemperature dependence titration 
To study the temperature dependence of the binding enthalpy, an alternative method was 
developed that allowed for maximal sample savings. Antibody (10 µM) solutions were 
injected in 11 µl steps into the sample cell containing 2 ml EGFR (2 µM) in a temperature-
changing titration that was executed as follows: the titration was started at 20°C, 3 to 5 titrant 
injections were performed at this temperature; afterwards, the titration was paused and the 
temperature was changed to 25°C and after temperature stabilization another 2 to 4 injections 
were performed; this process was repeated at 29 and at 33°C. Binding enthalpies were 
determined by averaging the peak areas determined for the multiple peaks. The titration was 
designed in such a way that the inflection of the curve took place at 33°C. After the inflection 
point, the peaks obtained enabled correction of the enthalpy values obtained. 
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5.5 24BStatic light scattering 
Analytical SEC/static light scattering (SLS) studies were performed to determine the size of 
complexes formed in EGFR/mAb and EGFR/Fab samples. An Agilent 1200 HPLC system 
from Agilent (Böblingen, Germany) was used. Light scattering data for protein eluting from 
the SEC column were collected using a multi-angle light scattering detector DAWN-
HELEOS-II from Wyatt Technologies (Dernbach, Germany). A  refractive index detector 
Optilab rEX, also from Wyatt Technologies was used as concentration detector. The data 
were analyzed using the Astra V software (Wyatt Technologies). 
 
Studies of EGFR mixtures with matuzumab and cetuximab Fab fragments were done at a flow 
rate of 0.3 ml/min by injecting 20 l protein solution onto a Superdex 200 GL analytical SEC 
column (GE Healthcare) equilibrated in PBS buffer, pH 7.4. Studies of EGFR mixtures with 
panitumumab and nimotuzumab Fabs, whole antibodies and antibody combinations were 
done at a flow rate of 0.05 ml/min by injecting 20 l protein solution onto a Superose 6 PC 
3.2/30 analytical SEC column (GE Healthcare) equilibrated in PBS buffer, pH 7.4. 
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6 5BRESULTS 
6.1 25BCharacterization of EGFR interactions with surface plasmon 
resonance 
 
6.1.1 40BKinetics of antibody and Fab fragments binding EGFR 
The binding kinetics of EGFR/mAb or EGFR/Fab was determined by surface plasmon 
resonance (SPR) /Biacore. Representative results of different assay configurations used are 
shown in Fig. 8. A closer look at the binding curves in Fig. 8 shows that the kinetic profile of 
the antibodies studied is conserved like a fingerprint in all tested assay design alternatives. 
Matuzumab is characterized by a very fast dissociation of the complex. In the other extreme is 
panitumumab that, among the mAbs studied, forms the most stable complex with EGFR. 
Cetuximab has a very similar kinetic profile to panitumumab, although the dissociation is 
somewhat faster for panitumumab-EGFR complex. Nimotuzumab is characterized by the 
slowest association rate, as observed by a longer association phase that takes longer to reach 
equilibrium.  
 
Best fit values of 1:1 binding model to the experimental data delivered the association rate 
(ka) and dissociation rate (kd) constants presented in Fig. 8 for each assay design used. The 
equilibrium dissociation constant (KD) was calculated from the rate constants ratio.  
 
Good overall consistency was observed between kinetic results obtained by the protein A 
/mAb assay (first row of Fig. 8) and by the immobilized EGFR /Fab assay (fourth row of Fig. 
8). Obtaining comparable results from such distinct assays shows robustness of the kinetic 
determination. Moreover, agreement of antibody and Fab fragment results indicates 
independence of both antibody arms binding to EGFR. The direct immobilization of mAbs 
(second row) or Fab fragments (third row) delivered lower association rate constant values 
although dissociation rates are consistent with those obtained by protein A or EGFR 
immobilization. 
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(1.22 ± 0.08) x106 M-1s-1
(1.52 ± 0.09) x10-3 s-1
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(6.0 ± 0.3) x105 M-1s-1
(5.72 ± 0.09) x10-4 s-1
(9.5 ± 0.6) x10-10 M
(3.5 ± 0.2) x104 M-1s-1
(2.05 ± 0.02) x10-3 s-1
(5.9 ± 0.4) x10-8 M
(4.3 ± 0.9) x104 M-1s-1
(1.02 ± 0.08) x10-2 s-1
(2.4 ± 0.3) x10-7 M
ka
kd
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(6.8 ± 0.4) x104 M-1s-1
(3.23 ± 0.18) x10-4 s-1
(4.7 ± 0.5) x10-9 M
(9.91 ± 0.05) x103 M-1s-1
(2.19 ± 0.013) x10-2 s-1
(2.21 ± 0.02) x10-7 M
(6.03 ± 0.05) x104 M-1s-1
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(7.76 ± 0.19) x105 M-1s-1
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(3.31 ± 0.14) x10-4 s-1
(4.5 ± 0.6) x10-10 M
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(1.71 ± 0.03) x10-3 s-1
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(8 ± 2) x10-9 M
 
Fig. 8: Kinetics and affinity of antibodies and Fab fragments binding to EGFR. 
SPR analysis of mAb binding was performed with capture of mAb on protein A that had been directly amine coupled 
to the biosensor chip (first row) or with direct amine coupling of the mAb itself (second row). In both cases, EGFR 
was passed over the surface as analyte. Analysis of Fab fragments was performed with direct amine coupling of the 
Fab to the biosensor surface (third row) and EGFR as analyte. Alternatively, EGFR was amine coupled to the 
biosensor surface and solutions Fab fragments were titrated as analyte (fourth row). Twofold serial dilutions of 
analyte covered a concentration range 1.5 - 800 nM. 1:1 binding model was fit to all experiments. For the model fitting 
not all concentrations were used, the higher concentrations were left out in some cases due to insufficient fitting. 
Values presented are the average of two independent determinations. 
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Fig. 9: Temperature dependence of antibody/EGFR kinetics and affinity.  
EGFR twofold serial dilutions covering a concentration range 1.5 - 800 nM were passed over each antibody captured on protein A surface. 1:1 Interaction model was fitted to all the 
experiments. For the model fitting not all concentrations were used, the higher concentrations were left out in some cases due to insufficient fitting. Values presented are the average of 
two independent determinations. 
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6.1.2 41BTemperature dependence of antibody/EGFR kinetics 
The temperature dependence of the EGFR/mAbs binding kinetics EGFR is shown in Fig. 9. 
Global fitting of binding data to 1:1 binding models yielded temperature-dependent rate 
constants and equilibrium constants also summarized in Fig. 9. The affinity weakened with 
increasing temperature from 15°C to 40°C for all four mAbs tested. In every case, the 
temperature dependence of KD is due to an increase in the dissociation rate constant, which 
can also be observed from the binding curves shown in Fig. 9. A slight increase in the 
association rate is also observed. 
 
6.1.3 42BTemperature dependence of ligand/EGFR affinity 
Interactions between EGFR and two natural ligands, EGF and TGF-α, were studied with SPR 
at different temperatures. The results are shown in Fig. 10. The binding curves of EGF and 
TGF-α binding to immobilized EGFR were evaluated by steady state analysis, yielding the 
equilibrium dissociation constants KD summarized in Fig. 10. 
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Fig. 10: Temperature dependence of ligand/EGFR kinetics and affinity.  
EGF and TGF-α twofold serial dilutions covering concentration ranges 3.9 - 2000 nM and 7.8 - 4000 nM, 
respectively, were passed over EGFR surface. The binding curves were evaluated with steady state analysis to 
yield KD. Values presented are the average of two independent determinations. 
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6.1.4 43BVan’t Hoff analysis 
The temperature dependent equilibrium constants of EGFR/mAb and EGFR/ligand binding 
determined by SPR analysis (see Fig. 9 and Fig. 10) were used to estimate binding enthalpies 
and entropies by plotting ln(KD) versus 1/T. The resulting van’t Hoff plots are shown for 
antibodies and ligands in Fig. 11. Linear fitting yielded the regression lines and the resulting 
thermodynamic properties also presented in Fig. 11. 
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matuzumab 
R2= 0.9969 
∆H25°C= (-77 ± 7) kJ 
-T∆S25°C= (33 ± 7) kJ 
 
cetuximab 
R2= 0.9947 
∆H25°C= (-69 ± 3) kJ 
-T∆S25°C= (18 ± 3) kJ 
 
panitumumab 
R2= 0.9933 
∆H25°C= (-52 ± 5) kJ 
-T∆S25°C= (0 ± 5) kJ 
 
nimotuzumab 
R2= 0.9921 
∆H25°C= (-98 ± 4) kJ 
-T∆S25°C= (57 ± 4) kJ 
 
EGF 
R2= 0.8848 
∆H25°C= (20 ± 4) kJ 
-T∆S25°C= (-58 ± 4) kJ 
 
TGF-α 
R2= 0.6014 
∆H25°C= (16 ± 5) kJ 
-T∆S25°C= (-49 ± 5) kJ 
Fig. 11: Van’t Hoff analysis of antibody/EGFR and ligand/EGFR affinity results. 
Antibody KD values were kinetically determined by SPR while ligand KD values were determined by steady state 
analysis of SPR binding curves. Error bars indicate the standard deviation on two independent measurements – 
see Fig. 9 and Fig. 10. Linear regressions were fitted to the van’t Hoff values; Coefficient of determination (R2) 
and thermodynamic results are presented on the right.  Legend:  EGF;  TGF-α;  matuzumab;  cetuximab;  
 panitumumab;  nimotuzumab.  
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6.1.5 44BAnalysis of maximal EGFR binding capacity on antibody surfaces 
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Fig. 12: SPR saturation studies of EGFR on oriented mAb (upper) and Fab (down) surfaces.  
Upper: matuzumab, cetuximab and nimotuzumab were captured by protein A surface; Lower: Fab fragments of 
matuzumab and nimotuzumab were captured by Biacore human Fab binder. Levels of theoretical Rmax were 
calculated with the capture level and the molecular weights of mAbs/Fabs and EGFR. Two independent batches 
of nimotuzumab were analyzed. Titrated concentrations of EGFR were 400, 800, 1600 and 3200 nM for mAbs 
matuzumab and cetuximab; 400, 800, 1600, 3200 and 6400 nM for Fab matuzumab and 400, 800, 1600, 3200, 
6400 and 12800 nM for mAb and Fab nimotuzumab. Panitumumab was not measured. Note: The results are 
from single experiments. 
 
With the objective of corroborating stoichiometric evidence provided by ITC and SLS with an 
orthogonal method, SPR saturation studies of EGFR in antibody surfaces were performed. 
The resulting sensorgrams are shown in Fig. 12 for whole antibodies (upper) and Fab 
fragments (lower). The antibodies were captured in a controlled manner by protein A directly 
immobilized on the biosensor surface. With the capture level and the molecular weights of 
EGFR and mAbs, the theoretical saturation level (Rmax) was calculated and is represented in 
Fig. 12 (upper) for the hypothetical binding stoichiometries EGFR:mAb 1:1 and 2:1. The 
obtained Rmax for EGFR binding to matuzumab and cetuximab surfaces is comparable and 
lays between the theoretical Rmax calculated for the two considered stoichiometries. This 
result is in accordance with a 2:1 stoichiometry of these antibodies. The Rmax observed for 
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EGFR on nimotuzumab surface was well below the other two antibodies but slightly above 
the theoretical Rmax calculated for stoichiometry 1:1. This shows a different stoichiometric 
profile of nimotuzumab when compared with the other antibodies and is coherent with the 
lower extent of bivalent binding observed for nimotuzumab in ITC and SLS analyses (Fig. 16 
and 20). 
 
The Fab fragments of matuzumab and nimotuzumab were captured by Biacore human Fab 
binder that had been directly immobilized on the biosensor surface (Fig. 12 lower). The 
values of Rmax obtained for EGFR binding to captured matuzumab and nimotuzumab Fab 
fragments lay below the theoretical Rmax calculated for a stoichiometry 1:1. For comparable 
capture levels of Fab fragments, nimotuzumab Fab fragment offered lower EGFR binding 
capacity. This result is coherent with ITC analysis of Fab fragments (Fig. 17). 
 
6.1.6 45BLigand competition analysis of antibodies 
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Fig. 13: Ligand competition properties of anti-EGFR antibodies. 
Competition experiments showing the effect of addition of anti-EGFR mAbs upon the binding of 800 nM EGFR 
to immobilized EGF. Mixtures of 800 nM EGFR plus the indicated concentrations of mAbs were passed over a 
biosensor surface to which EGF had been amine coupled. The equilibrium SPR responses for each mixture is 
shown, normalized to the response obtained with no added mAb. Error bars indicate the standard deviation on 
two independent measurements. The line simply connects the data points. 
 
Competition assays were carried out to investigate the ability of the anti-EGFR mAbs in study 
to compete with ligand binding to EGFR. The binding of EGFR to immobilized EGF at 
different concentrations of anti-EGFR mAbs was tested. The results are shown in Fig. 13. For 
antibodies cetuximab, panitumumab and nimotuzumab, at a molar ratio above 1:1 of 
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EGFR:mAb, SPR response is below 10 % of that obtained with no added mAb (see close up). 
In the case of matuzumab, there is an initial decrease in the equilibrium SPR response as 
increasing mAb is added. At a 1:1 molar ratio of EGFR:matuzumab the SPR response is about 
40 % of that obtained with no added mAb. Addition of increasing excesses of matuzumab 
does not further reduce this binding level.  
 
6.1.7 46BAntibodies binding to EGFRvIII 
The variant III mutation of EGFR (EGFRvIII) is an EGFR mutant where nearly the whole of 
domains I and II are missing, while domains III and IV are unaltered. Thus, analysis of the 
binding to this mutant allows considerations about epitope positioning relating to EGFR 
extracellular domains to be done. Surface plasmon resonance (SPR)/Biacore experiments 
were carried out to characterize the binding kinetics of cetuximab, panitumumab and 
nimotuzumab binding to EGFRvIII. Solutions with different concentrations of EGFRvIII were 
titrated to protein A captured mAbs. For comparison purposes, wild type EGFR (EGFRwt) 
was titrated in the same assay construction. The kinetic results are summarized in Table 3. 
Matuzumab was not included in the analysis. 
 
Table 3: SPR results of binding kinetics and affinity of mAbs binding to EGFR wild type (EGFRwt) and 
variant III (EGFRvIII).  
Interaction ka (M-1s-1) kd (s-1) KD (M) 
Cetuximab – EGFRwt 9.7 x105 0.0015 1.5 x10-9 
Cetuximab – EGFRvIII 2.5 x106 0.0011 4.5 x10-10 
Panitumumab – EGFRwt 4.6 x105 6.7 x10-4 1.5 x10-9 
Panitumumab – EGFRvIII 1.3 x106 5.0 x10-4 3.8 x10-10 
Nimotuzumab – EGFRwt 8.9 x104 0.0012 1.3 x10-8 
Nimotuzumab – EGFRvIII 4.8 x105 7.8 x10-4 1.6 x10-9 
Note: The results with EGFRvIII are single measurements; the results with EGFRwt are the average of two 
independent measurements. 
 
6.1.8 47B inding interdependence of antibody combinations to EGFR 
SPR was applied to study how the anti-EGFR mAbs in study influence each other upon 
binding to EGFR. Two experimental setups were developed. The first was a sandwich setup 
where a second mAb was titrated to a controlled density of EGFR previously captured by 
directly immobilized mAb – Fig. 14. This assay setup provided real time monitoring of mAb 
binding to “un-crosslinked” EGFR. However, the rapid dissociation of EGFR from the 
surface, especially in the case of immobilized matuzumab, hindered observation of the 
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binding curves of the second antibody. A second setup was developed with crosslinking of 
EGFR to the first antibody, thus disabling the dissociation of EGFR from the immobilized 
antibody – Fig. 15. The second assay setup could thus be used as control to the results 
obtained with the first setup. However, binding may be influenced by EGFR crosslinkage. 
Moreover it should be tested if the crosslinkage itself happens in an oriented way to assure 
that simultaneous binding of mAbs is actually observed. Positive and negative control 
experiments were included to check the activity of EGFR molecules and that (epitope, steric, 
allosteric) interdependence was conserved after crosslinkage. For both SPR setups, negative 
controls were provided by the titration of the same mAbs as the immobilized ones. For the 
second SPR setup, the pair cetuximab/panitumumab provided a further negative control, since 
these antibodies cross-blocked each other in the first setup. Positive control for the second 
SPR setup was provided by the pairs that showed simultaneous binding in the first setup: 
matuzumab/cetuximab and matuzumab/nimotuzumab. These controls showed that EGFR 
remains active after crosslinking. However, steady state analysis of the binding curves 
obtained for the simultaneous binding of these pairs with crosslinked EGFR showed that 
mAb/EGFR affinity could be 100 times weaker after crossblocking (Table 4) and therefore 
the results obtained from the second setup remain qualitative. 
 
Both assay orientations of the matuzumab/cetuximab pair yield SPR concentration-dependent 
binding curves – Fig. 14. The same effect is observed for the pair matuzumab/nimotuzumab. 
Steady state analysis of cetuximab and nimotuzumab binding to matuzumab-complexed 
EGFR yielded affinity values comparable to free EGFR affinity – Table 4. Matuzumab 
binding curves to cetuximab- or nimotuzumab-complexed EGFR yielded stronger affinity 
values than to free EGFR – Table 4. The matuzumab/EGFR binding is stronger in the 
presence of one other antibody binding simultaneously to EGFR. One probable explanation 
for this is the slower dissociation rate observed for the matuzumab/EGFR complex when 
cetuximab or nimotuzumab simultaneously bind EGFR, as observed in Fig. 14 in comparison 
to Fig. 8. The simultaneous binding of matuzumab/cetuximab and matuzumab/nimotuzumab 
to EGFR was confirmed by the second SPR setup, involving EGFR crosslinkage – Fig. 15. 
Both orientations of the cetuximab/panitumumab sandwich assay configuration showed no 
binding detectable upon titration of the second antibody, indicating that these antibodies 
crossblock each other upon EGFR binding – Fig. 14 and Fig. 15. The titrations cetuximab to 
nimotuzumab-bound EGFR and panitumumab to matuzumab- or nimotuzumab-bound EGFR 
yielded negative binding curves that follow a concentration dependency – Fig. 14. 
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Matuzumab titrated to panitumumab-bound EGFR delivers initially positive concentration-
dependent binding curves that after a few seconds result in negative response. Reverse 
titrations delivered a similar but weaker effect, indicating asymmetry of the phenomenon. 
Analysis of the antibody combinations cetuximab/nimotuzumab, panitumumab/matuzumab, 
and panitumumab/nimotuzumab with the second SPR experimental setup involving EGFR 
crosslinking showed simultaneous binding of the two antibodies to EGFR – Fig. 15.  
 
Table 4: Comparison of mAbs affinity to free, mAb-captured and mAb-crosslinked EGFR (SPR results). 
mAb …binding to EGFR KD (M) 
free 2 x10-8 
captured by cetuximab 8 x10-9 
captured by nimotuzumab 4 x10-9 
crosslinked to cetuximab (control) 5 x10-8 
crosslinked to nimotuzumab (control) 4 x10-8 
Matuzumab 
crosslinked to panitumumab 2 x10-6 
free 1 x10-9 
captured by matuzumab 4 x10-9 
crosslinked to matuzumab (control) 1 x10-7 Cetuximab 
crosslinked to nimotuzumab 2 x10-7 
free 1 x10-9 
crosslinked to matuzumab 6 x10-7 Panitumumab 
crosslinked to nimotuzumab 8 x10-7 
free 6 x10-8 
captured by matuzumab 9 x10-8 
crosslinked to matuzumab (control) 6 x10-7 
crosslinked to cetuximab  - 
Nimotuzumab 
crosslinked to panitumumab - 
Note: The results are from single experiments. 
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Fig. 14: SPR analysis of antibodies binding interdependence with transiently captured EGFR.  
Each of the four anti-EGFR mAbs in study (columns) was titrated to biosensor surfaces where EGFR had been 
captured by each of the amine coupled mAbs (rows). The sensorgrams shown have been subtracted by reference 
surfaces with the same level of immobilized mAb where EGFR has not been passed over. The level of EGFR 
capture in each mAb surface is shown in the figure. Concentrations of mAb solutions titrated were 1.5, 3, 6, 12, 
25, 50, 100, 200, 400, 800, 1600 and 3200 nM. Shown results are representative of two independent 
measurements. 
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Fig. 15: SPR analysis of antibodies binding interdependence with covalently crosslinked EGFR. 
Each of the four anti-EGFR mAbs in study (columns) was titrated to biosensor surfaces where EGFR had been 
crosslinked to each of the amine coupled mAbs (rows). The sensorgrams shown have been subtracted by 
reference surfaces with the same level of immobilized mAb where EGFR has not been passed over. The level of 
mAb binding in each surface is shown in the figure. Concentrations of mAb solutions titrated were 1.5, 3, 6, 12, 
25, 50, 100, 200, 400, 800, 1600 and 3200 nM. Shown results are representative of two independent 
measurements. 
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6.2 26BCharacterization of EGFR interactions with isothermal 
titration calorimetry  
6.2.1 48BLigand and antibody titrations to EGFR 
ITC analyses were performed by titrating (injecting) ligands or antibodies to the EGFR 
solution placed in the calorimeter cell. The differential power signals recorded (raw data), and 
the data integration points fitted to single-site binding isotherms are presented in Fig. 16. 
Titrations of ligands EGF and TGF-α into EGFR result in positive differential power signal, 
indicating that the reaction is endothermic (Fig. 16). The opposite is true for titrations of 
antibodies; here, negative differential power signal are indicative of exothermic reactions. 
 
Isothermal titration calorimetry analysis delivers direct measurements of stoichiometry (N), 
equilibrium association constant and enthalpy of binding (∆H). The results of single-site 
binding isotherms fitted to the data integrated points are presented in Fig. 16 to the respective 
ITC experiments. For comparison purposes with SPR results and since it is the most 
commonly used affinity measure, the equilibrium association constant was converted into 
equilibrium dissociation constant (KD). Analyses have been normalized for binding sites to 
enable direct comparison between mAb (two binding sites), ligands (one binding site) and Fab 
fragments (one binding site) – see Fig. 17.  
 
Stoichiometry results of ligands/EGFR were approx. 1 mol ligand /mol EGFR. The 
interactions of mAbs matuzumab, cetuximab and panitumumab yielded approx. 1 mol mAb 
binding sites /mol EGFR. Since antibody molecule has two binding sites, 1 mol mAb binding 
sites / mol EGFR translates to one mAb molecule binding two EGFR. The stoichiometry of 
nimotuzumab/EGFR interaction was atypical 1.4 mol mAb binding sites /mol EGFR, which 
translates into one mAb molecule binding between one and two EGFR. 
 
The ligand EGF binds EGFR with stronger affinity than does TGF-α, although less enthalpy 
is absorbed by the system upon binding of TGF-α. Both ligands show weaker EGFR affinity 
than the four antibodies studied. Affinities of the strong binders cetuximab and panitumumab 
could not be delivered since the titration curves are too steep for reliable determination. All 
four mAbs/Fabs mean relatively similar enthalpy changes upon EGFR binding. The largest 
binding enthalpy is released upon EGFR interaction with matuzumab. Panitumumab 
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interaction, on the other hand, involves the smallest enthalpy release of the four antibodies 
studied. 
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Best fit parameters: 
N= 0.84 ± 0.03 
KD= (9.7 ± 7) x10-8 M 
∆H= 54 ± 2 kJ 
TGF-α 
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Best fit parameters: 
N= 1.10 ± 0.03 
KD= (4.0 ± 0.7) x10-7 M 
∆H= 38 ± 2 kJ 
matuzumab 
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Best fit parameters: 
N= 0.89 ± 0.03 
KD= (7.1 ± 0.3) x10-9 M 
∆H= -77 ± 2 kJ 
cetuximab 
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Best fit parameters: 
N= 0.88 ± 0.01 
KD= < 2 x10-9 M 
∆H= -70 ± 5 kJ 
panitumumab 
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Best fit parameters: 
N= 0.84 ± 0.03 
KD= < 2 x10-9 M 
∆H= -51.9 ± 0.6 kJ 
nimotuzumab 
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Best fit parameters: 
N= 1.39 ± 0.01 
KD= (24 ± 2) x10-9 M 
∆H= -56.9 ± 0.5 kJ 
Fig. 16: ITC analysis of antibody/EGFR and ligand/EGFR interactions. 
For each ligand and antibody studied, the ITC results shown are representative of two independent 
measurements at 25°C and the best fit parameters are the average of the two measurements. The upper plot 
represents the raw data or heat of binding following each injection; the lower plot shows the integrated results, 
where each point represents the normalized heat change for each injection.  
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6.2.2 49BAntibody Fab fragment titrations to EGFR 
Fab matuzumab 
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Best fit parameters: 
N= 0.87 
KD= 4.9 x10-9 M 
∆H= -78 kJ 
Fab cetuximab 
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Best fit parameters: 
N= 0.94  
KD= < 2 x10-9 M 
∆H= -72 kJ 
Fab panitumumab 
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Best fit parameters: 
N= 0.86 
KD= < 2 x10-9 M 
∆H= -44 kJ 
Fab nimotuzumab 
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Best fit parameters: 
N= 1.6 ± 0.01 
KD= (3.1 ± 0.5) x10-8 M 
∆H= -45 ± 2 kJ 
Fig. 17: ITC analysis of antibody Fab fragments/EGFR interactions. 
For Fab matuzumab, Fab cetuximab and Fab panitumumab, the ITC results shown are single measurements at 
25°C. For Fab nimotuzumab, the result is representative of two independent measurements at 25°C and the best 
fit parameters are the average of the two measurements. The upper plot represents the raw data or heat of 
binding following each injection; the lower plot shows the integrated results, where each point represents the 
normalized heat change for each injection. 
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Calorimetric analyses were performed by titrating (injecting) antibody Fab fragments to the 
EGFR solution placed in the calorimeter cell. Results are shown in Fig. 17. Affinity and 
enthalpy results are comparable to the ones obtained for the whole antibodies, thus indicating 
that the two antibody binding sites bind to EGFR independently. The interactions with 
matuzumab, cetuximab and panitumumab Fab fragments delivered consistent stoichiometric 
results of approx. 1 mol Fab /mol EGFR. Nimotuzumab Fab stoichiometric result was atypical 
1.6 mol Fab /mol EGFR, which is coherent with the results obtained for the antibody – see 
Fig. 16.  
 
6.2.3 50BTemperature dependence of antibody/EGFR binding enthalpy 
A method was developed that involved aliquot injection at different temperatures in the same 
titration, with temperature stabilization time before sample injections (Fig. 18). This allowed 
important material savings, since binding enthalpy was obtained for four different 
temperatures (20°C, 25°C, 29°C and 33°C) with the material needed for one titration. Binding 
enthalpies determined at each of the temperatures are represented by open circles (	) in the 
plots ∆H versus T in Fig. 18. Full titrations were performed for matuzumab and cetuximab at 
20°C, 25°C and 33°C. The binding enthalpies obtained from full titrations are represented   by 
closed circles () in the plots ∆H versus T in Fig. 18. As can be seen for matuzumab and 
cetuximab, the enthalpy values obtained by the temperature change titration correlate well 
with the values obtained from full titrations. As seen in Fig. 18, matuzumab, panitumumab 
and nimotuzumab interactions to EGFR are associated with a negative dependence of 
enthalpy with the temperature. The change in heat capacity ∆Cp° = A(∆H)/AT is obtained from 
the slopes of plots ∆H versus T. Results of linear regression to the data shown in Fig. 18 are 
summarized in Table 5. A negative change in heat capacity was determined for matuzumab, 
panitumumab and nimotuzumab respectively. As for cetuximab, no clear temperature 
dependence of binding enthalpy could be established, due to high scattering of the data points. 
 
Table 5: Heat capacity change of antibody/EGFR binding. 
Antibody Regression R2 ∆Cp° (kJ/mol/K) 
Matuzumab 0.9757; 0.9877 -1.7 ± 0.3 
Cetuximab 0.8537; 0.0637 -0.3 ± 0.5 
Panitumumab 0.946 -0.83 ± 0.14 
Nimotuzumab 0.6887 -1.3 ± 0.6 
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Fig. 18: Temperature dependence of antibody/EGFR binding enthalpy.  
Binding enthalpy at different temperatures was measured in one single calorimetric titration (left hand plots) 
and is represented in plots of ∆H vs. Temperature by  (right hand plots). Error bars indicate the standard 
deviation on at least two ITC injections. For matuzumab and cetuximab, full titrations were also done at 20°C 
and 33°C (293K and 306K); these are represented on the right hand plots by . 
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6.2.4 51B inding interdependence of antibody combinations to EGFR 
To investigate the interdependence of antibody combinations binding to EGFR, antibodies 
were titrated to EGFR solutions containing saturating molar amounts of another antibody. 
Calorimetric titrations of antibodies to different mAb combinations are shown in Fig. 19. Raw 
data were left out for simplification and the fitted models of titrations to mAb-saturated EGFR 
were overlapped with titrations to free EGFR. A closer look to Fig. 19 shows unchanged 
stoichiometry (molar ratio in the titration inflection point) observed for titrations to bound 
EGFR of mAb combinations matuzumab/cetuximab (first row) and matuzumab/nimotuzumab 
(second row). This means that interaction of one of these antibodies with mAb-complexed 
EGFR is thermodynamically identical to interaction with free EGFR. The affinity (slope in 
the titration inflection point) calculated in experiments of simultaneous binding is 
comparable, or enhanced in case of matuzumab, to the affinity of free EGFR binding. The 
calculated binding enthalpy (titration curve amplitude) of matuzumab or cetuximab titrated to 
bound EGFR is somewhat lower than to free EGFR. However, this is compensated by a lower 
entropic penalty resulting in overall comparable binding strength. Additionally, the titration of 
a matuzumab/cetuximab antibody mixture to free EGFR (Fig. 19) resulted in a stoichiometry 
of two mAb binding sites per EGFR molecule, in accordance with the simultaneous binding 
of matuzumab and cetuximab to EGFR. Here again, a lower enthalpic contribution seems to 
be compensated by a lower entropic penalty, resulting in comparable average mAb/EGFR 
affinity. ITC titrations of panitumumab to matuzumab- (third row) or nimotuzumab-saturated 
EGFR (fourth row in Fig. 19) resulted in the detection of positive enthalpy changes. Overlay 
of the binding isotherms obtained from titrations of mAbs to free EGFR shows that the 
positive enthalpy change measured corresponds to the difference between the negative 
enthalpy changes of matuzumab and panitumumab upon EGFR binding. This suggests that 
upon addition of panitumumab, matuzumab or nimotuzumab molecules previously bound to 
EGFR are substituted by panitumumab molecules. No measurable ITC signal was detected 
upon interdependence titrations of the antibody combinations cetuximab/nimotuzumab and 
panitumumab/cetuximab (fifth row). 
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Fig. 19: ITC analysis of antibodies binding interdependence. 
Binding to EGFR was tested for the different combinations of therapeutic antibodies. Over each plot is described the 
respective experiment, e.g. matuzu  cetuxi|EGFR means matuzumab titrated to cetuximab-saturated EGFR. Raw data were 
left out for simplification. Isotherms of ITC analysis to free EGFR are shown in overlay. The one-sites model was fitted to all 
titrations shown except for the titrations panitumu  matuzu|EGFR and panitumu  nimotuzu|EGFR, where competition 
model was fitted. The results are from single experiments.  
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6.3 27BCharacterization of EGFR interactions with static light 
scattering 
6.3.1 52BSize of complexes formed in antibody/EGFR mixtures 
Static light scattering was used to determine the size of complexes formed in mixtures of 
EGFR with anti-EGFR antibodies matuzumab, cetuximab, nimotuzumab and panitumumab. 
Samples of EGFR and mAb controls as well as EGFR/mAb mixtures with different molar 
ratios were injected into the SEC-LS/UV/RI system separately. Representative 
chromatograms of EGFR/mAb mixtures and respective controls are shown in Fig. 20. The red 
line in the chromatograms represents the average molecular weight detection of eluting 
molecules, calculated by static light scattering analysis. The black line is the refractive index 
detection, directly proportional to protein concentration. Molecular weight results are 
summarized in Table 6. In a first approach, the molecules used were characterized. Apparent 
molecular weights of 97,000, 160,000, 162,000, 154,000 and 154,000 Da were measured for 
EGFR, matuzumab, cetuximab, panitumumab and nimotuzumab, respectively. The molecular 
weight obtained for EGFR indicates that the receptor exists as a monomer in solution under 
the conditions used. Primary structure information reveals a predicted protein molecular 
weight of approx. 70,000 for EGFR and a total molecular weight, including glycosylation of 
105,000 (Weber et al., 1984; Ullrich et al., 1984; Stroop et al., 2000). Molecular weights 
obtained for the mAbs are in agreement with typical sizes for antibodies of the IgG type 
(Stanfield and Wilson, 2009). The molecular weight distribution of peaks in control 
chromatograms is horizontal (Fig. 20) indicating size monodispersity of the eluting molecules. 
The calculated molecular weights of EGFR and mAb controls are all in agreement with 
predicted and published results, showing validity of the results and applicability of the 
method. 
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Fig. 20: Light scattering analysis of mixtures of mAb/EGFR mixtures.  
Controls and mixtures were injected separately into the SEC-LS/UV/RI system. Molecular weight (red line) was 
determined by light scattering using peak protein concentration calculated by refractive index detection (black 
line). Heterodimer and heterotrimer sizes were predicted using EGFR and mAb calculated molecular weights 
and were marked in the chromatograms of mixtures by and  respectively. The results are from single 
experiments. The results are from single experiments. 
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Table 6: Summary of light scattering results obtained for mAb/EGFR mixtures and controls.  
Mixture Molar ratio Molecular weight of first 
eluting species (Da) 
EGFR (control) -   97,000 
Matuzumab (control) - 160,000 
Cetuximab (control) - 162,000 
Panitumumab (control) - 154,000 
Nimotuzumab (control) - 154,000 
1:1 315,000 
EGFR:matuzumab 
2.5:1 340,000 
1:1 380,000 
EGFR:cetuximab 
2.5:1 380,000 
1:1 350,000 
EGFR:panitumumab 
2.5:1 370,000 
0.5:1 250,000 
1:1 258,000 
2:1 310,000 
2.5:1 320,000 
EGFR:nimotuzumab 
3:1 340,000 
Note: The results are from single experiments. However, their validity was confirmed by additional analysis of 
mAb/EGFR mixtures at different molar ratios and/or using a different SEC column (data not shown). 
 
The mixtures of EGFR with mAbs all resulted in peaks eluting earlier than the mAb or EGFR 
controls (Fig. 20). This indicates that complexes were formed in all mixtures. The molecular 
weight distribution of peaks in chromatograms of mixtures is not constant over peak elution 
(RI detection). This is indicative of peak polydispersity caused by poor chromatographic 
resolution achieved with the SEC column used. Poor chromatographic resolution is also 
indicated by overlapping elution peaks seen from the RI detection. Nevertheless, the 
molecular weight maximum coincides with the maximum signal for protein elution (RI 
maximum). It should be kept in mind that the molecular weight detection performed delivers 
an average value for the molecules eluting at a given moment. In mAb/EGFR mixtures with 
EGFR excess, maximum average molecular weight values of 340,000, 380,000 and 370,000 
Da were reached. Complex molecular sizes are consistent with the predicted sizes of 
heterotrimers (one mAb and two EGFR molecules), calculated using the molecular weight 
results of controls. Therefore, the bivalent EGFR binding of the antibodies studied is 
corroborated.  
 
The average molecular weight of complexes formed in EGFR/nimotuzumab mixtures is lower 
in comparison with the other three mAbs. At an EGFR-to-nimotuzumab ratio of 1, the 
maximum of average molecular weight corresponds approximately to the predicted 
heterodimer size, while matuzumab, cetuximab and panitumumab correspondent mixtures 
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deliver average molecular weights well above this value. In the case of cetuximab and 
panitumumab, heterotrimer sizes are already detected. The maximal average molecular weight 
of EGFR/nimotuzumab complexes increases with increasing EGFR-to-mAb ratios of 2, 2.5 
and 3 (Table 6). An increase in the peak polydispersity was also observed in such mixtures, as 
can be seen in Fig. 20 for the highest ratio studied, 3. The average molecular weight detection 
in this chromatogram indicates a strongly polydisperse sample; average molecular weight 
detection does not reach a stable (maximum) level. However, high molecular weight 
complexes could be observed, especially at the front of the peak where the molecular weight 
detection line reaches the heterotrimer size. The results indicate that heterotrimers exist in 
lower concentration than observed for matuzumab, cetuximab and nimotuzumab. Existing 
heterotrimers probably co-elute with heterodimers, free EGFR and maybe even free mAb 
molecules. That explains the lower average molecular weight and the polydispersity of the 
sample.  
 
6.3.2 53BSize of complexes formed in antibody Fab fragment/EGFR mixtures 
Representative chromatograms of EGFR/Fab fragments mixtures and the respective controls 
are shown in Fig. 21 and calculated molecular weights are summarized in Table 7. The 
molecular weights of the fragments were calculated as 47,000, 51,000, 47,000 and 55,000 for 
matuzumab, cetuximab, panitumumab and nimotuzumab Fab respectively; all are in 
agreement with typical Fab fragments sizes. The calculated molecular weights of EGFR and 
Fab molecules were used to predict the sizes of expected eluting complexes – heterodimers – 
represented in the chromatograms of mixtures by horizontal lines (Fig. 21). The molecular 
weight distribution of the first eluting peak of Fab/EGFR mixtures attained the 145,000 in the 
case of Fab matuzumab. As for the Fabs cetuximab, panitumumab and nimotuzumab, 
maximal sizes 140,000, 165,000 and 150,000 were attained. Mixtures with molar excess of 
Fab fragments were analyzed in order to test the hypothesis of various Fabs binding to one 
EGFR molecule (e.g. antibody bivalency). The results indicate that all Fab fragments form 
heterodimer complexes with EGFR. Trimers were not detected. 
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Fig. 21: Light scattering analysis of mixtures of Fab fragment/EGFR mixtures. 
Controls and mixtures were injected separately into the SEC-LS/UV/RI system. Molecular weight (red line) was 
determined by light scattering using peak protein concentration calculated by refractive index detection (black 
line). Heterodimer sizes were predicted using EGFR and Fab calculated molecular weights and were marked in 
the chromatograms of mixtures by . The results are from single experiments. 
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Table 7: Summary of light scattering results obtained for Fab fragment/EGFR mixtures and controls.  
Mixture Molar ratio Molecular weight of first 
eluting species (Da) 
EGFR (control) -  97,000 
Fab matuzumab (control) -  47,000 
Fab cetuximab (control) -  51,000 
Fab panitumumab (control) -  47,000 
Fab nimotuzumab (control) -  55,000 
1:1 140,000 
EGFR:Fab matuzumab 
1:2.5 145,000 
1:1 125,000 
EGFR:Fab cetuximab 
1:2.5 140,000 
EGFR:Fab panitumumab 1:1 165,000 
1:1 130,000 
EGFR:Fab nimotuzumab 
1:2.5 150,000 
Note: The results are from single experiments. However, their validity was confirmed by additional analysis of 
mAb/EGFR mixtures at different molar ratios and/or using a different SEC column (data not shown). 
 
 
6.3.3 54BSize of complexes formed in mixtures of EGFR with antibody 
combinations 
Static light scattering was applied as orthogonal method to corroborate the observations of 
simultaneous binding of distinct antibodies to EGFR seen in Fig. 14 and Fig. 19. Samples of 
EGFR and mAb combinations with different molar ratios were injected into the SEC-
LS/UV/RI system separately and the sizes of complexes formed in such mixtures were 
calculated. Representative chromatograms of EGFR/matuzumab/cetuximab and 
EGFR/matuzumab/nimotuzumab mixtures are shown in Fig. 22, together with the 
chromatograms obtained for samples with only one type of antibody. Molecular weights 
calculated for EGFR, matuzumab, cetuximab and nimotuzumab (Table 8) were used to 
predict the size of hypothetical quatromer complexes (formed by two EGFR and two different 
mAb molecules). Quatromer complexes are the simplest complexes consistent both with the 
bivalent EGFR/antibody binding and the simultaneous binding of different antibody 
molecules. Predicted quatromer sizes were represented in the chromatograms of 
heterogeneous mAb mixtures by horizontal lines (Fig. 22). The maximum average molecular 
weight of heterogeneous mAb mixtures corresponds to the predicted size of heterogeneous 
quatromers. Table 8 summarizes the SLS results of all the antibody combinations tested. 
Complexes formed in mixtures of EGFR with matuzumab/cetuximab and 
matuzumab/nimotuzumab reached maximal molecular weights of 550,000 and 500,000 
respectively. Mixtures formed with EGFR and the antibody combinations 
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matuzumab/panitumumab, cetuximab/panitumumab and panitumumab/nimotuzumab yielded 
maximal average molecular weights of 370,000, 350,000 and 350,000, respectively. 
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Fig. 22: Light scattering analysis of mixtures of EGFR and combinations of mAbs.  
Controls and mixtures were injected separately into the SEC-LS/UV/RI system. Molecular weight (red line) was 
determined by static light scattering using peak protein concentration calculated by refractive index detection 
(black line). Sizes were predicted for heteroquatromers using EGFR and mAb calculated molecular weights 
(Table 1) and were marked in the chromatograms by . The results are from single experiments. 
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Table 8: Summary of light scattering results obtained for EGFR and mAb mixtures. 
Mixture Molar ratio Molecular weight of first 
eluting species (Da) 
EGFR:matuzumab (control) 2.5:1 340,000 
EGFR:cetuximab (control) 2.5:1 380,000 
EGFR:panitumumab (control) 2.5:1 370,000 
EGFR:nimotuzumab (control) 3:1 340,000 
2.5:0.5:1 500,000 
2.5:1:0.5 500,000 
1:1:1 550,000 
EGFR:matuzumab:cetuximab 
2.5:1:1 550,000 
2.5:0.5:1 370,000 
2.5:1:0.5 350,000 
1:1:1 360,000 
EGFR:matuzumab:panitumumab 
2.5:1:1 360,000 
2.5:0.5:1 490,000 
2.5:1:0.5 410,000 EGFR:matuzumab:nimotuzumab 
1:1:1 500,000 
2.5:0.5:1 350,000 
2.5:1:0.5 340,000 EGFR:cetuximab:panitumumab 
1:1:1 320,000 
2.5:0.5:1 330,000 
2.5:1:0.5 350,000 EGFR:panitumumab:nimotuzumab 
1:1:1 350,000 
Note: The results are from single experiments. 
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7 6BDISCUSSION 
7.1 28BAntibodies bind EGFR bivalently 
Antibodies are bivalent molecules; they have two identical binding sites situated in the two 
Fab regions. However, the binding of both antibody arms may be dependent on steric 
allowance. This is especially true for big antigens, such as EGFR. Two different possibilities 
were assumed for the stoichiometry of EGFR/mAb complexes: 
• stoichiometry 1:1, corresponding to the binding of one EGFR molecule to each mAb 
molecule and the consequent formation of a heterodimer; 
• stoichiometry 2:1, corresponding to the binding of two EGFR molecules to each mAb 
molecule and the consequent formation of a heterotrimer. 
As for the complexes formed between EGFR and Fab fragments, a stoichiometry 1:1 was 
expected.  
 
Table 9: Stoichiometry results from ITC analysis of mAb/EGFR and Fab fragment/EGFR. 
mAb/Fab titrated to EGFR Stoichiometry, N  
Matuzumab 0.9 mol mAb binding sites / mol EGFR 
Cetuximab 0.9 mol mAb binding sites / mol EGFR 
Panitumumab 0.8 mol mAb binding sites / mol EGFR 
Nimotuzumab 1.4 mol mAb binding sites / mol EGFR 
Fab matuzumab 0.9 mol Fab / mol EGFR 
Fab cetuximab 0.9 mol Fab / mol EGFR 
Fab panitumumab 0.9 mol Fab / mol EGFR 
Fab nimotuzumab 1.6 mol Fab / mol EGFR 
Note: mAb results are the average of the two ITC measurements (see Fig. 16); Fab results are from single 
measurements (see Fig. 17), except Fab Nimotuzumab result, which is the average of the two ITC 
measurements. 
 
Stoichiometric evidence obtained by ITC confirmed the bivalent binding of matuzumab, 
cetuximab and panitumumab (Table 9). For these mAbs, isothermal titration calorimetry 
analysis yielded stoichiometry values of approx. 1 mol mAb binding sites /mol EGFR, 
corroborating the stoichiometry EGFR:mAb 2:1. Small deviations to N=1 are usually 
observed with ITC as a result of errors in the concentration determination of the protein 
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solutions used. The total protein concentration of the solutions used for the study was 
determined by UV measurements at 280 nm. This method requires knowing the extinction 
coefficient of the molecules present in solution. The extinction coefficient can be estimated by 
the Edelhoch method (Edelhoch, 1967) when the primary structure of the protein is known. 
This was done for EGFR, matuzumab and cetuximab, whose primary structures are known. In 
the case of panitumumab and nimotuzumab, where primary structures have not been 
published, the nominal protein concentration given in the vial was assumed. For these two 
antibodies, a typical extinction coefficient for antibodies of the IgG type was used 
alternatively for protein determination. Even if estimated by the Edelhoch method, protein 
extinction coefficients are rarely known better than 5%, and are usually worse (Cooper, 
2001). Accuracy problems in protein determination, resulting either from poor estimated 
extinction coefficients, or from limitations of the UV measurement technique (Cooper, 2001), 
are a common source of small errors in stoichiometry (N) measured by ITC. These are 
probably the cause for the deviations from N=1 observed for matuzumab, cetuximab and 
panitumumab. The stoichiometric results observed for nimotuzumab will be discussed in the 
next section (section 7.2). 
 
Bivalent binding of matuzumab, cetuximab and panitumumab were confirmed by SLS 
studies, where mixtures of EGFR with each of the three mAbs yielded average molecular 
weights of complexes formed that agreed with the predicted size of heterotrimers (see Fig. 20 
and Table 6). These results indicated that heterotrimers were already present when the EGFR-
to-mAb molar ratio was as low as 1. Bivalent binding of matuzumab and cetuximab was also 
confirmed by saturation experiments of EGFR on SPR surfaces where controlled levels of 
matuzumab and cetuximab had been captured (see Fig. 12). These results show that the EGFR 
saturation level is well above the theoretical binding level expected for a monovalent 
interaction, almost reaching the theoretical binding level expected for a bivalent interaction.  
 
Cetuximab and matuzumab bivalency has previously been shown by gel electrophoresis 
separation of crosslinked cell lysates (Fan et al., 1994; Yoshida et al., 2008). Bivalency of 
panitumumab is, to the best of my knowledge, reported in this study for the first time. 
Bivalency, and the consequent capacity to form antibody-mediated EGFR dimers, is believed 
to play a critical role in the anti-tumor efficacy of EGFR antibodies (Rehder et al., 2008; 
Rudnick and Adams, 2009).  Since antibody-antigen binding is a reversible and concentration 
dependent association, bivalent binding of mAb to EGFR has advantages for blockade of 
receptor activity. If one arm of the bivalent antibody temporarily dissociates from an EGFR, 
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the other arm may still adhere to another receptor on the cell surface, allowing the dissociated 
arm to reassociate (Fan et al., 1994). This effect is known as avidity and it reduces drastically 
the dissociation of antibodies from the surface of tumor cells. Moreover, bivalency is 
responsible for a higher rate of EGFR endocytosis and consequent down-regulation (Friedman 
et al., 2005).  
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Fig. 23: Overlays of ITC mAb and Fab /EGFR isotherms.  
Titration raw data were left out for simplification; the isotherms presented are the result of one-sites model fits. 
In reddish colour are presented the titrations of mAb and Fab nimotuzumab with corrected concentration to yield 
stoichiometry 1 mol mAb binding site and 1 mol Fab /EGFR (see explanation in section 7.2). mAb 
measurements were repeated twice (see Fig. 16); Fab results are from single measurements (see Fig. 17), except 
Fab Nimotuzumab result, which was repeated twice. 
 
Despite a relatively large receptor size, the observed antibody bivalency demonstrates that 
there is no steric hindrance between EGFR molecules binding to both arms of the same 
antibody. Moreover, studies of EGFR binding to Fab fragments, indicate that the binding 
events occurring in both antibody arms are independent. Kinetic/affinity analysis performed 
with optimal configuration surface plasmon resonance assays delivered very similar results 
for the whole antibodies and the respective Fab fragments (see Fig. 8). Also isotherms fitting 
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to ITC analysis of mAb or Fab binding to EGFR are almost indistinguishable, as seen in Fig. 
23 for the four antibodies in study.  
 
7.2 29BNimotuzumab is partly unfunctional 
ITC-originated stoichiometry results for nimotuzumab/EGFR interaction (Table 9) apparently 
indicate a mixed stoichiometry of EGFR:mAb binding between 1:1 and 2:1 and a mixed 
stoichiometry of EGFR:Fab binding between 1:1 and 2:1. The different assembly state 
hypotheses and corresponding expected stoichiometry for mAb/EGFR and Fab/EGFR are 
shown in Fig. 24. For the interactions of matuzumab, cetuximab and panitumumab with 
excess EGFR, hypothesis C and E were validated (see section 7.1). The validity of the 
hypothesis presented and explanations for nimotuzumab atypical results are discussed in this 
section. 
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results
 
Fig. 24: Representation of the different possible assembly states for mAb/EGFR and Fab/EGFR 
complexes. 
For mAb/EGFR interaction, three assembly states were considered as possible: A) Binding of only one antibody 
arm to one EGFR molecule, while the other arm is free – corresponding stoichiometry EGFR:mAb 1:1, or mol 
mAb-binding-sites /mol EGFR = 2; B) Binding of both antibody arms to only one EGFR molecule – 
corresponding stoichiometry EGFR:mAb 1:1, or mol mAb-binding-sites /mol EGFR = 2; C) Binding of one 
antibody to two EGFR molecules – corresponding stoichiometry EGFR:mAb 2:1, or mol mAb-binding-sites 
/mol EGFR = 1. For Fab/EGFR interaction, two assembly states were considered as possible; D) Binding of one 
Fab fragment to two EGFR molecules – corresponding stoichiometry EGFR:Fab 1:2, or mol Fab fragment /mol 
EGFR = 2; E) Binding of one Fab fragment to one EGFR molecule – corresponding stoichiometry EGFR:Fab 
1:1, or mol Fab fragment /mol EGFR = 1. 
 
Hypotheses B and D would correspond to nimotuzumab having two different binding sites, 
i.e., the antibody would be bi-specific. However, bispecificity is not described in the 
literature; on the contrary, nimotuzumab is reported as an IgG1 type humanized antibody 
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(Boland and Bebb, 2009). Light scattering analysis of Fab/EGFR mixtures deliver complex 
size agreeing with heterodimer size, thus corroborating hypothesis E and denying hypothesis 
D. This is consistent with published results where the bivalence of nimotuzumab/EGFR 
interaction has been proclaimed (Tikhomirov et al., 2008). Moreover, if the two Fab regions 
of nimotuzumab would bind the same EGFR molecule, then these two binding events would 
not be independent, but rather the binding of the second arm would occur with a higher 
probability than the first, due to a higher chance of two molecules finding each other. 
However, kinetic, affinity and thermodynamic results of Fab fragments binding to EGFR 
agree with whole antibody results (see Fig. 8 and Fig. 23), corroborating independence of 
binding events taking place in both antibody arms. Thus, based on independence of antibody 
binding arms and on the size of complexes formed in nimotuzumab Fab fragment /EGFR 
mixtures, hypotheses B and D are discarded. 
 
With hypothesis D discarded, the only possible assembly state for Fab fragment/EGFR 
interaction is represented by hypothesis E. As for whole antibody stoichiometry, possible 
assembly states for nimotuzumab/EGFR complexes are represented by hypotheses A and C, 
i.e. monovalency or bivalency of antibody. Light scattering analysis indicates the existence of 
heterotrimers in nimotuzumab/EGFR mixtures, thus corroborating assembly state hypothesis 
C (see Fig. 20). However, the average size of the eluting complexes in nimotuzumab/EGFR 
mixtures is smaller than for those formed by matuzumab, cetuximab and panitumumab 
mixtures. This could be caused by lower concentration of heterotrimers and co-elution of 
these with smaller species (heterodimers and free mAbs or EGFR). But why would 
nimotuzumab /EGFR mixtures yield lower heterotrimer concentration than matuzumab, 
cetuximab and panitumumab /EGFR mixtures?  
 
Nimotuzumab has the weakest affinity of all studied mAbs (Fig. 8) and this could be a reason 
for the lower extent of complex formation. Yet, nimotuzumab /EGFR affinity is in the 
nanomolar range and the SLS experiments were performed in the micromolar range, so that 
the concentration of interactants is way above the affinity. Also, if weak affinity could explain 
the lower degree of complex formation in nimotuzumab /EGFR mixtures, and provided both 
antibody binding sites are independent, the same effect should be seen in Fab nimotuzumab 
studies. However, Fab nimotuzumab /EGFR mixtures deliver SLS results that are comparable 
to the other three Fab fragments analysed (see Fig. 20); the molecular weight of complexes 
formed corresponds to the expected size of heterodimers. Therefore, weaker affinity can not 
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be the cause – or the only cause, at least – for the lower heterotrimer concentration observed 
in nimotuzumab /EGFR mixtures. Other causes are further discussed. 
 
There could be a concentration error in nimotuzumab ITC samples. However, for both 
panitumumab and nimotuzumab, the UV-determined protein concentration agreed well with 
the nominal vial concentration, thus indicating that total protein concentration is correct. 
Moreover, comparison of different dilutions of the four antibodies in study by SDS-PAGE 
(data not shown) also corroborated the nominal vial concentration of nimotuzumab, thus not 
supporting the hypothesis of an error in total antibody concentration. Moreover, identical 
quantity of nimotuzumab and other antibodies used as controls – shown by a comparable 
surface capture level – bound less EGFR molecules in SPR (see Fig. 12). This evidence is 
independent from the original nimotuzumab concentration in solution, since the same quantity 
was captured for each antibody, thus corroborating that the total concentration of 
nimotuzumab is correct.  
 
The cause for nimotuzumab/EGFR lower heterotrimer concentration could be that a part of 
nimotuzumab molecules in solution are unable to build heterotrimers, i. e. they have one (or 
both) unfunctional arms. If part of the molecules in solution has one unfunctional arm, then 
nimotuzumab/EGFR mixtures would yield a mix of assembly states A and C. The 
independence of binding events occurring in both antibody arms has been evidenced by 
comparing kinetic and thermodynamic results. As a consequence of yielding identical 
thermodynamic profiles, the nimotuzumab populations leading to assembly states A and C 
would be indistinguishable by ITC. Calorimetric titration of such a mixture could explain the 
symmetric isotherm observed for the interaction of nimotuzumab to EGFR (Fig. 16) and the 
atypical “hybrid” stoichiometric results.  If part of the molecules in solution has both 
unfunctional arms, then these molecules would not bind EGFR. The nimotuzumab solution 
would simply be a mix of binding-capable and binding-incapable antibodies and in this case 
the assembly state would be represented by hypothesis C. The binding-incapable antibodies 
present in solution would lead to an error in active concentration of nimotuzumab and reflect 
in the stoichiometry obtained from ITC. Accordingly, the generation of Fab fragments from 
this solution would naturally yield a mixture of binding and non-binding Fab fragments, thus 
also explaining the results for Fab/EGFR stoichiometry. Comparative SEC/SLS analysis of 
solutions of the four mAbs in study showed that the content of soluble aggregates present in 
the nimotuzumab solution is less than 5% (Fig. 25). Such low aggregate content could not 
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possibly explain the error in active concentration of nimotuzumab. Moreover, nimotuzumab 
molecules are captured by protein A (see Fig. 12), meaning that the protein A binding site in 
the Fc part of the antibody is intact. 
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Fig. 25: SEC/SLS analysis of antibody samples.  
Nimotuzumab solution shows presence of less than 5% of soluble aggregates (estimated aggregate size: dimers). 
In Y-Axis-2 is represented the dRI signal, indicative of protein concentration. 
 
With the results at hand, no final conclusions can be taken regarding the reasons for 
nimotuzumab lower heterotrimer concentration and “hybrid” ITC stoichiometry results. The 
hypotheses of part of nimotuzumab molecules having one or both unfunctional binding sites 
remain open. ITC delivers a direct measure of stoichiometry, provided the active 
concentration of both interactants is accurately entered for isotherm fitting. As speculative 
exercise, the nimotuzumab mAb and Fab concentration values entered for fitting of ITC 
results were iteratively changed until stoichiometry 1 mol mAb binding site and 1 mol Fab 
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/EGFR were obtained (Fig. 23). The entered concentration that yielded the referred 
stoichiometry values was, for both mAb and Fab solutions, around 60% of the nominal 
concentration, meaning that around 40% of the nimotuzumab binding sites would be inactive. 
Speculation can be exercised about what could be the cause beneath the estimated 40 % 
partial or totally inactive antibody molecules present in solution. Monoclonal antibodies are, 
by definition, antibody molecules produced by descendents of one single clone only (therefore 
monoclonal). The molecules are thereby ideally all perfect copies of each other. However, 
achieving and proving monoclonality is a very exigent task. The presence of two binding 
populations in the nimotuzumab solution (namely monovalent-binders and bivalent binders) 
can be the result of glycosilation or post-translational modifications. Glycosylation is 
potentially important for the binding of the antibodies to their targets and can be variably 
accomplished by the producer organism machinery, being a potential source of binding 
heterogeneity. Post-translational modifications of the molecules can happen during production 
or storage and can affect the binding properties of the molecules. For example, isomerization 
of a single residue present in the CDR region of panitumumab has been shown to deeply 
affect the binding to EGFR (Rehder et al., 2008). Such results suggest the importance of 
designing molecules with “robust” primary structures, that can be more resistant to post-
translational modifications and thus yield more homogeneous protein products. 
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7.3 30BInterdependence of antibodies binding to EGFR 
Motivated by reports of synergic effects of anti-EGFR mAbs (Friedman et al., 2005; Dechant 
et al., 2008; Meira et al., 2009), biophysical methods were applied to test the interdependence 
of mAbs binding to EGFR. The results obtained with SPR, ITC and SLS are summarized on 
Table 10. Based on these results, the interdependence of different mAb combinations binding 
to EGFR could be divided in three modes: 
• Simultaneous binding; 
• Displacement; 
• Crossblocking. 
 
Table 10: Summary of results obtained upon analysis of mAbs interdependence with biophysical methods. 
Experimental observations 
mAbs 
interdependence 
mAbs 
mixture with 
EGFR SPR without 
crosslinking 
(see Fig. 14) 
SPR with 
crosslinking 
(see Fig. 15) 
ITC 
 
(see Fig. 19) 
SLS 
 
(see Fig. 22) 
matuzu;  
cetuxi 
positive 
binding curves 
positive  
binding curves 
strong 
negative 
enthalpy 
change 
size of complexes 
corresponds to 
quatromer 
Simultaneous 
binding 
matuzu; 
nimotuzu 
positive  
binding curves 
positive  
binding curves 
strong 
negative 
enthalpy 
change 
size of complexes 
corresponds to 
quatromer 
matuzu; 
panitumu 
negative  
binding curves 
positive  
binding curves 
positive 
enthalpy 
change 
complexes size 
unchanged by the 
presence of second 
mAb 
nimotuzu; 
panitumu 
negative  
binding curves 
positive  
binding curves 
positive 
enthalpy 
change 
complexes size 
unchanged by the 
presence of second 
mAb 
Displacement 
nimotuzu; 
cetuxi 
negative  
binding curves 
positive  
binding curves no signal 
complexes size 
unchanged by the 
presence of second 
mAb 
Crossblocking cetuxi; panitumu no signal no signal no signal 
complexes size 
unchanged by the 
presence of second 
mAb 
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USimultaneous binding 
The antibody pairs matuzumab/cetuximab and matuzumab/nimotuzumab are able to bind 
simultaneously to EGFR. The affinity of matuzumab to EGFR is actually improved by the 
presence of either cetuximab or nimotuzumab. According to SPR results, this is related with a 
slower dissociation rate of the complex when compared to the dissociation of the complex 
formed with free EGFR (Fig. 14). This effect can be explained by avidity. Since the 
antibodies bind bivalently, the less probable simultaneous dissociation of both antibody arms 
is needed for dissociation of complex. In the case of cetuximab and nimotuzumab, the overall 
affinity (avidity) of EGFR binding is not improved by the presence of a second antibody 
binding simultaneously to EGFR. These antibodies have slower dissociation rates from free 
EGFR, so that the effect of avidity is less important and the affinity to mAb-complexed or 
free EGFR is comparable. In thermodynamic terms (Fig. 19), although the simultaneous 
binding is at least as favourable as the binding of one single antibody, the calculated binding 
enthalpy (titration curve amplitude) of matuzumab or cetuximab titrated to bound EGFR is 
somewhat lower than to free EGFR. This effect may be due to steric or allosteric hindrance of 
individual non-covalent interactions, although as proven by the affinity results, the overall 
interaction is at least as strong. In general, the simultaneous binding of anti-EGFR mAbs to 
EGFR is enabled by non-overlapping epitopes and simultaneous absence of steric hindrance 
between both antibodies.  
 
Antibody cocktails have proven increased efficacy for a number of targets (Logtenberg, 
2007). Their response involves a series of direct and indirect effector mechanisms that include 
neutralization, phagocytosis, complement-mediated destruction and antibody-mediated 
cellular cytotoxicity. These are elicited by the concerted action of different species of 
antibodies that have multiple specificities, bind several epitopes (antigens) and act in synergy. 
Synergic effects of the combined use of matuzumab and cetuximab are known (Friedman et 
al., 2005; Kamat et al., 2008; Dechant et al., 2008; Meira et al., 2009). Moreover, the 
hypothesis of simultaneous binding to EGFR had already been presented as possible 
explanation for the synergic effects (Kamat et al., 2008). This hypothesis was corroborated by 
the completely non-overlapping epitopes of both antibodies (Li et al., 2005; Schmiedel et al., 
2008). The present work presents for the first time SPR and ITC evidence of the simultaneous 
binding of these two anti-EGFR mAbs. The simultaneous binding of matuzumab and 
nimotuzumab is described for the first time. A synergic effect could thus be expected from the 
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combined use of matuzumab and nimotuzumab in the clinic. However, such study was 
beyond the scope of this thesis. 
 
A B1 B2
 
Fig. 26: Representation of the different possible assembly states for matuzumab/cetuximab and 
matuzumab/nimotuzumab complexes. 
Possible assembly states for mAb-1/EGFR/mAb-2 complexes are: A) closed cycles formed of two EGFR and 
two different mAb molecules; B1) chains of intercalated mAb /EGFR molecules with variable length; B2) chains 
of intercalated mAb /EGFR molecules whose ends can eventually interact with each other. 
Legend: red circle – EGFR; black y-shape – mAb-1; grey y-shape – mAb-2. 
 
Light scattering analysis was used to further investigate such EGFR-mediated bi-antibody 
complexes (see Fig. 22). Results show a maximal average molecular weight of complexes 
formed in mixtures of EGFR with matuzumab/cetuximab or matuzumab/nimotuzumab that 
corresponds to the predicted size of heterogeneous quatromers (two EGFR and two different 
mAb molecules) – see Fig. 22. This result corroborates the simultaneous binding of these two 
pairs of antibodies to EGFR and indicates the formation of quatromers as preferred complex 
assembly state. However, the spatial arrangement of such assembly state could not be 
precisely determined and the question if these complexes build closed cycles (A in Fig. 26) or 
open chains (B in Fig. 26) remains open. The co-existence of both open and closed quatromer 
complexes depends on how flexible and sterically free the EGFR epitopes of both mAbs are. 
Moreover, the existence of larger assembly state configurations, simply pictured as variable 
size chains of intercalated mAb /EGFR molecules, cannot be excluded. The co-elution of 
larger hetero-complexes with simple one-mAb heterotrimers, heterodimers or even free 
monomers could explain the average molecular weight obtained. However, this possibility is 
not supported by the results, since the molar mass detection line of the mixtures does not 
indicate the presence of larger complexes. If the complexes are in the open chain 
configuration, then a high variability of the chain length can be envisaged and it is very 
probable that chains longer than quatromers exist. It is possible that such long chains would 
have less resistance to the sheer stress offered by the SEC column used for separation and 
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eventually break into smaller ones during the chromatographic process, explaining the 
quatromer-like size of complexes detected by light scattering analysis.  
 
The size of EGFR-mediated bi-antibody complexes may have important implications in the 
clinic. It has been postulated that synergic effects of mAb combinations would be related to a 
higher rate of EGFR endocytosis and consequent down regulation of the receptor (Friedman 
et al., 2005). If the rate of EGFR clearance from the cell surface is proportional to the size of 
EGFR-mAb lattices, then the bigger these lattices are, the faster and more efficiently EGFR 
can be down-regulated. Alternatively, synergic effects could be related to potent activation of 
complement-dependent cytotoxicity against EGFR-expressing cells (Dechant et al., 2008). 
 
UDisplacement 
Negative concentration-dependent SPR binding curves were observed during interdependence 
studies for the antibody pairs matuzumab/panitumumab, nimotuzumab/cetuximab and 
nimotuzumab/panitumumab (see Fig. 14). These are indicative of cross-competition between 
these antibodies; binding of the second antibody to EGFR produces dissociation of the 
receptor from the first antibody, leading to the observed negative concentration-dependent 
curves. This hypothesis has been corroborated by ITC for the pairs matuzumab/panitumumab 
and nimotuzumab/panitumumab (see Fig. 19). Competitive fit to such ITC experiments 
yielded the same enthalpy change for panitumumab/EGFR as the one obtained from free 
EGFR titration, indicating that the detected heat was the difference between the heat released 
upon panitumumab/EGFR association and the heat uptaken upon matuzumab/EGFR or 
nimotuzumab/EGFR dissociation. In both SPR and ITC analysis, this interdependence mode 
was asymmetric. Cetuximab completely rescued EGFR from nimotuzumab while 
nimotuzumab itself was less efficient in binding cetuximab-bound EGFR. Panitumumab 
competed with both matuzumab and nimotuzumab but none of these two antibodies was as 
efficient in displacing panitumumab. The observed asymmetry is probably due to differences 
in affinity: cetuximab and panitumumab are strong binders while matuzumab and 
nimotuzumab bind to EGFR with lower affinity. The competition of cetuximab to 
nimotuzumab was not detectable by ITC, possibly due to cancellation of the enthalpic 
contributions from both antibodies upon EGFR binding.  
 
Similar SPR interdependent studies, where the second antibody was titrated to EGFR that had 
been cross-linked to the immobilized antibody showed simultaneous binding for the pairs 
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referred above (see Fig. 15). This indicates that, to a certain extent, the epitopes are non-
overlapping and there is steric allowance for simultaneous binding of both antibodies to 
EGFR. Thus, the dissociation from the first (immobilized) antibody observed in Fig. 14 could 
be explained by a conformational change induced by the second antibody to EGFR weakening 
the binding to the first antibody. The hypothesis of conformational change of EGFR upon 
antibody binding indicates that the interaction that takes place is not a rigid body-like 
interaction. The initially positive binding curves observed for matuzumab binding to 
panitumumab-captured EGFR are believed to be the detection of the complex matuzumab-
EGFR-panitumumab and corroborate the hypothesis of short-lived simultaneous binding of 
both antibodies. Such complexes were not directly detectable in any other of the pairs tested. 
It is possible that the complex was made detectable in the special case of 
panitumumab/matuzumab by a coincident favourable combination of kinetic rates. Since the 
crosslinkage of EGFR seems to affect its binding affinity to the positive controls, 
considerations about the affinity of antibodies from the pairs above binding to crosslinked 
EGFR were not done. Controls show that affinity is affected at different degrees by 
crosslinking, possibly due to partial loss of complex flexibility or EGFR activity.  
 
UCrossblocking 
The third mode of mAb interdependence is crossblocking, as observed for cetuximab and 
panitumumab. Antibodies cetuximab and panitumumab compete with each other for EGFR 
binding, the binding of one making the binding of the other impossible (see Fig. 14). This can 
be due to EGFR overlapping epitopes and/or to strong steric or allosteric hindrance.  Point 
mutations in EGFR revealed critical for both cetuximab and panitumumab binding, indicating 
strong overlapping of the epitopes of both antibodies (Freeman et al., 2008). 
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7.4 31BConsiderations about epitope and allostery mapping 
Cetuximab, panitumumab and nimotuzumab all bind to EGFRvIII (Table 3). This result is 
consistent with their interactions with epitopes situated in domain III of EGFR (Fan et al., 
1994; Li et al., 2005; Freeman et al., 2008; Talavera et al., 2009). Moreover, kinetic analyses 
by SPR show that these antibodies bind EGFRvIII more tightly than the wild type receptor. 
The same effect was previously shown for matuzumab (Schmiedel, 2009) and is possibly due 
to the absence of steric hindrance from the domains I and II nearly completely missing in 
comparison to full length EGFR. Cetuximab, panitumumab and nimotuzumab block ligand 
binding to EGFR, while matuzumab is not able to completely block the binding of the soluble 
receptor to immobilized EGF. Instead the equilibrium SPR response plateaus at 40% of the 
value in the absence of antibody. EGF competition results are in agreement with published 
results (Yang et al., 2001; Li et al., 2005; Schmiedel et al., 2008; Talavera et al., 2009). The 
fact that matuzumab does not completely block EGF binding is consistent with a non 
overlapping epitope with the EGF binding site on domain III (Schmiedel et al., 2008). One 
possible explanation for the observed SPR responses is that both unbound EGFR and the 
EGFR complex can interact with the immobilized EGF, but that the complex binds with 
substantially weaker affinity.  
 
Based on the above discussion and on interdependence studies discussed in section 7.3, a map 
of the relative epitope positions and binding interdependence of the four anti-EGFR 
antibodies studied was developed (Fig. 27). In this map, the epitopes of matuzumab (M), 
cetuximab (C), panitumumab (P) and nimotuzumab (N) are represented by circles of different 
colours. They are all situated on domain III of EGFR. Cetuximab, panitumumab and 
nimotuzumab epitopes strongly overlap with the EGF binding site. Matuzumab, on the 
contrary, binds to an epitope that does not overlap with the EGF binding site. The epitopes of 
cetuximab and panitumumab strongly overlap and they are both able to displace 
nimotuzumab. However, and interestingly, only panitumumab displaces matuzumab 
(cetuximab binds EGFR simultaneously with matuzumab). 
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Fig. 27: Relative epitope position and allosteric displacement of anti-EGFR mAbs. 
Grey area - domain III of EGFR; white area - EGF binding site within domain III; red - matuzumab epitope; blue 
- cetuximab epitope; purple - panitumumab epitope; green - nimotuzumab epitope.  
 
 
7.5 32BKinetics of antibody/EGFR binding 
Cetuximab and panitumumab are the two strong affinity antibodies, although the kinetic 
reasons for their strong affinities are distinct (see Fig. 8). Cetuximab binding to EGFR 
delivered the highest association rate from all four antibodies in study. The strong affinity of 
panitumumab is explained by the slowest dissociation of all EGFR-mAb interactions studied. 
Matuzumab and nimotuzumab are the two weak affinity antibodies of the lot. 
Matuzumab/EGFR complexes are the less stable ones, as indicated by a high dissociation rate 
constant. The weak nimotuzumab affinity is due to a low association rate.  
 
Careful SPR assay design and development is essential for obtaining good quality kinetic data 
and meaningful rate and equilibrium constants of binding. Therefore, some considerations 
about assay design will be done. The very first question in SPR assay development is which 
interactant to immobilize. Multivalent interactants, like antibodies, are preferably 
immobilized. This avoids avidity effects arising if they are passed over in solution. The anti-
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EGFR mAbs in study were either directly immobilized by amine coupling or captured by 
protein A (Fig. 8). 
 
Excellent overall consistency was observed between kinetic results obtained when EGFR was 
titrated to protein A-captured antibodies and when Fab fragments were titrated to directly 
immobilized EGFR. Obtaining comparable results from such distinct assays shows robustness 
of the kinetic determination. Moreover, both assays delivered the fastest association rate 
constants for all antibodies studied, and consequently lower KD values, indicating optimal 
assay configuration. Optimal assay configuration has been defined as the one which produces 
the strongest affinity between ligand and analyte (Patel and Andrien, Jr., 2009). The direct 
immobilization of antibodies or Fab fragments delivered lower association rate constant 
values although dissociation rates are consistent with those obtained by protein A or EGFR 
immobilization. Since this happened for all antibodies studied, it indicates a systematic error 
caused by the immobilization of either mAb or Fab fragment. Direct immobilization of 
antibodies may result in aleatory antibody orientation at the biosensor surface, since amine 
coupling will use any free amine groups at the surface of the protein. Protein A specifically 
binds the Fc part of antibodies. Thus, the capture alternative offers an oriented immobilization 
where steric hindrance is minimized and all binding sites are oriented towards the flow 
channel and thus available for EGFR binding. 
 
7.6 33BThermodynamics of antibody/EGFR binding 
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Fig. 28: Thermodynamic profiles of mAb/EGFR and ligand/EGFR interactions (ITC results). 
In pointed bars are presented the mAb and Fab nimotuzumab thermodynamics obtained from treating ITC 
analysis with corrected concentrations to yield stoichiometry 1 mol mAb binding site and 1 mol Fab /EGFR (see 
section 7.2). Thermodynamic profiles shown are the average of best fits to two independent ITC measurements 
(see Fig. 16). 
 
In the previous section, kinetic explanations for the different antibodies affinities were 
discussed. In this section, the thermodynamic reasons for the different affinities will be 
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highlighted. The thermodynamic profiles presented in Fig. 28 were constructed with results 
originated by ITC (see Fig. 16). The equilibrium constant values of cetuximab and 
panitumumab could not be determined accurately by simple ITC experiments due to their too 
steep isotherm curves, indicative of a KD value lower than 2 nM. The KD value of 
panitumumab/EGFR interaction, and consequently the Gibb’s energy change, ∆G, could be 
quantified from the ITC analysis of panitumumab to matuzumab-saturated EGFR (Fig 19). 
Competitive fit of that interaction yielded ∆H of -49 kJ/mol, a value comparable to the one 
obtained by simple interaction (-52 kJ/mol, Fig 16) and thus indicating validity of this 
determination. The resulting KD value was 0.2 nM. Similar results were obtained for the 
panitumumab titration to nimotuzumab-saturated EGFR: KD 0.1 nM and ∆H -45 kJ/mol. 
These results were obtained when the concentration of nimotuzumab was corrected to yield a 
stoichiometry of 1 mol antibody binding sites / mol EGFR from the fitting of a one-sites 
isotherm to the nimotuzumab/EGFR titration raw data (Fig. 25). The same strategy could not 
be applied to calculate the affinity of cetuximab, since the cetuximab/nimotuzumab titration 
did not deliver measurable calorimetric detection. This was possibly due to a match of the 
binding enthalpies of cetuximab/EGFR and nimotuzumab/EGFR binding, that cancel each 
other upon competition. 
 
Matuzumab and cetuximab have close enthalpy contributions; a lower entropic penalty seems 
to be the reason for cetuximab stronger affinity. Panitumumab has the smallest enthalpy 
contribution of all four mAbs, that is compensated in terms of binding strength by a null or 
even slightly favourable entropic change. Enthalpy of binding is related to the difference in 
electrostatic interactions (H-bonds, van der Waals) that take place in the complex and in the 
interactants alone. Entropy of binding is related to the desolvation of surfaces upon bonding 
and conformational changes. Although cetuximab and panitumumab have very similar 
affinities and compete with each other for EGFR binding (see section 7.3), their 
thermodynamic profiles are quite different. This indicates that although interacting with 
comparable (overlapping) epitopes at the EGFR surface, the two antibodies probably do so in 
rather distinct modes. This allegation could only be done in view of the thermodynamic 
profiles (enthalpy and entropy) of the two antibodies. A strongly negative heat capacity 
change was observed for matuzumab, panitumumab and nimotuzumab. Negative heat 
capacity change has been correlated with the burial of non-polar groups upon binding.  
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Binding of antibodies and ligands to EGFR yielded opposite thermodynamic profiles. While 
antibody interactions are enthalpy-driven and mostly entropy-penalized, ligand interactions 
are entropy-driven and enthalpy-penalized. Enthalpy-driven reactions are typically related to 
polar interactions and are usually the case for antibody-antigen interactions (Sundberg and 
Mariuzza, 2002). Anti-EGFR antibodies bind and stabilize a tethered conformation of the 
receptor (Li et al., 2005; Schmiedel et al., 2008). It was seen by comparison of antibody-
complexed and monomeric EGFR that the binding of antibody does not seem to affect the 
structural conformation of EGFR extracellular domains (Li et al., 2005; Schmiedel et al., 
2008). Entropy-driven reactions, as observed for ligand/EGFR binding, have been related to 
conformational or dynamic (e.g. solvation, desolvation) changes. This result is coherent with 
structural studies. Ligands bind preferentially to an extended form of EGFR and “trap” the 
receptor in the conformation that can dimerize through the exposed dimerization arm. Since 
the receptor exists in solutions preferentially in the tethered conformation (Ferguson et al., 
2003), ligand binding has to induce a quite large-scale conformational change (Burgess et al., 
2003).  
 
The indirect determination of binding thermodynamics from the van’t Hoff treatment of 
temperature dependent equilibrium constants yielded by SPR analysis will be discussed in the 
next section.  
 
7.7 34BComparative evaluation of SPR, ITC and SLS 
The most significant characteristic of surface plasmon resonance /Biacore technology is the 
possibility of real time monitoring of macromolecular interactions. This enabled a wealth of 
information about mAb/EGFR interactions to be collected. Firstly, the calculation of binding 
kinetics provided a broader understanding about complex formation than equilibrium 
constants alone (see section 7.5). Secondly, SPR studies of different mAb combinations 
binding to EGFR were very helpful on clarifying the way antibodies influenced each other 
upon binding EGFR (see section 7.3). The advantage of SPR for this kind of study is evident 
in Fig. 14 and Fig. 15, where the binding of a second antibody to EGFR can be observed in 
real time. For this purpose, ITC could only deliver equilibrium data (Fig. 19) that would have 
been harder to interpret without the information collected with SPR. Moreover, since ITC 
relies on measurements of total heat released or absorbed in solution, false negatives can be 
obtained for reactions where the total heat is close to zero. That was the case for the antibody 
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pair cetuximab/nimotuzumab: although SPR analysis indicated that the binding of the second 
antibody lead to displacement of the first (Fig. 14), no signal could be measured by ITC (Fig. 
19). The two antibodies may have a close enthalpy change upon EGFR binding (Fig. 28), 
resulting in a total heat change close to zero. Another advantage of SPR is that it can be 
applied to a wide range of binding affinities, enabling the determination of affinities as strong 
as 10-10 M (Schuck et al., 2004). ITC applicability to study strong affinities (as often the case 
for antibody-antigen interactions) is limited. This was the case for cetuximab and 
panitumumab, whose EGFR affinity could not be accurately determined by a simple ITC 
experiment since the isotherm curves were too steep (see Fig. 16). However, SPR allowed 
affinity determinations of these two strong EGFR binders.  
 
Good correlation is observed between the affinity results obtained by ITC and by SPR for 
mAb/EGFR and ligand/EGFR interactions (Fig. 29). A systematic bias is observed: SPR 
originated KD values (KD(Biacore)) were generally higher than ITC ones (KD(ITC)), for all 
the interactions tested. This effect is possibly related to the immobilization of one interactant 
in SPR studies.  
 
0,1
10,0
1000,0
100000,0
0,1 10,0 1000,0 100000,0
log KD ITC
lo
g 
K D
 
Bi
ac
or
e
 
Fig. 29: Correlation of ITC and SPR-generated affinity results. 
The diagonal line represents a correlation of 1. Error bars indicate the standard deviation on two independent 
measurements. Legend:  EGF;  TGF-α;  matuzumab;  cetuximab;  panitumumab;  nimotuzumab;  
nimotuzumab with corrected concentration to yield N=1.  
 
Additionally to enabling real time monitoring of interactions, determination of binding 
kinetics and study of high affinity interactions, SPR also allowed for studying the 
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thermodynamics of antibody/EGFR. Although ITC remains the standard method for direct 
measurement of binding thermodynamics, the sample consumption can be very high. The 
relatively low material consumption makes SPR an interesting alternative for thermodynamic 
studies. In this study, design of SPR and ITC methods was oriented towards minimal 
consumption of EGFR material. ITC analysis consumed two times the material needed for 
thermodynamic analysis with SPR, respectively 0.4 mg and 0.2 mg. However, three days 
were needed to obtain thermodynamic information with SPR, while ITC results could be 
obtained in a couple of hours. Although good agreement of SPR-based and calorimetric 
thermodynamic parameters has been reported in the literature, most of these studies have been 
done for the interaction of small molecules or proteins with small molecules (Day et al., 2002; 
Myszka et al., 2003; Papalia et al., 2008). The extrapolation of such results to complex 
protein-protein interactions should be done with prudence. Protein-protein interactions are 
very complex. They result from multiple single interactions, involve the burial of large protein 
surface areas – 1,400 to 2,300 Å2 for antibody-antigen interactions (Sundberg and Mariuzza, 
2002) – and consequent displacement of solvent molecules and may also involve quite 
dramatic rearrangement of domains and conformational changes. 
 
Enthalpic and entropic changes were determined indirectly from the temperature dependence 
of KD using the van’t Hoff plot (see Fig. 11). Linear fitting of van’t Hoff plots presumes that 
the enthalpy change of reaction is constant with the temperature. However, the temperature 
dependence of enthalpy was determined by ITC (see Fig. 18) and this was only the case for 
cetuximab. Matuzumab, panitumumab and nimotuzumab have negative dependencies of 
enthalpy with the temperature and so the correct fit to the van’t Hoff plot is a quadratic 
function delivering ∆CP together with ∆H and ∆S. However, observation of the plots suggests 
that there would be no benefit in such a fitting, since the experimental error seems to be too 
high covering the curvature of the experimental points. Values of ∆CP thus determined would 
have very low significance. Thus, heat capacity change could not be determined by SPR due 
to a high results scattering in the van’t Hoff plot that masked the curvature expected from 
interactions whose enthalpy was not constant with the temperature.  
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Fig. 30: Correlation of ITC and SPR-generated thermodynamic results. 
The diagonal line represents a correlation of 1. Error bars indicate the standard deviation on two independent 
measurements. Legend:  EGF;  TGF-α;  matuzumab;  cetuximab;  panitumumab;  nimotuzumab;  
nimotuzumab with corrected concentration to yield N=1. 
 
The thermodynamic contributions ∆H and -T∆S calculated by SPR and ITC analysis are 
compared in Fig. 30. Very good correlation is observed for results of both methods for 
matuzumab, cetuximab and panitumumab interactions. As for nimotuzumab, ITC delivers 
lower enthalpic contribution as well as lower entropic penalty in comparison to SPR values. 
However, after correction of nimotuzumab concentration to yield EGFR:nimotuzumab 
stoichiometry of 2:1, there is an increase in both thermodynamic terms (Fig. 28) and a better 
correlation with SPR-based results is obtained. In SPR experiments EGFR is titrated to 
captured mAb and the affinity results thus originated are only dependent on the EGFR 
concentration. Therefore, an error in nimotuzumab concentration would normally not be 
propagated to the affinity results calculated by SPR. For the two agonists studied, EGF and 
TGF-α, the correlation between SPR and ITC thermodynamic parameters is poor and this can 
be due to the complexity of agonist/EGFR interactions. The binding of either EGF or TGF-α 
to EGFR involves a dramatic EGFR conformational change and results in dimerization of the 
receptor. Conformational change and receptor dimerization are thus equilibria linked to ligand 
binding and can take place with different extents in SPR and ITC, depending on conditions 
like rotational and diffusional freedom and concentration effects. Such effects could not be 
quantified and represent a deviation from the models used to fit SPR and ITC experimental 
results, respectively 1:1 binding model and one-sites model. Thus, the poor correlation 
observed for the agonist interactions is probably due to too simplistic data modelling in both 
methods, rather than to the methods themselves. Moreover, heterogeneities in ligand/EGFR 
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interaction affinities have highlighted the complexity and interdependence of the various 
linked equilibria that compose this complex interaction (Macdonald and Pike, 2008; Lemmon, 
2009). A poor fit of the 1:1 interaction model to SPR binding curves was actually observed, 
which is why affinity was calculated by steady state analysis. Other models of interaction 
were considered as possible ways to explain the interaction and fit the binding curves: the two 
state reaction model, accounting for the existence of a second reaction (EGFR conformational 
change and/or dimerization) linked to the first; and the heterogeneous ligand model, 
accounting for the existence of different immobilized interactants (different conformations – 
tethered, open, dimerized – of EGFR on the surface). Two-state reaction and heterogeneous 
ligand both yielded better fits to the raw data, but it is unclear how realistic or significant such 
analyses are or if the better fit is simply a result of a higher model flexibility. Since the fit of 
more complicated models to the SPR binding curves of agonists to EGFR could not be 
validated, it was decided to work with the steady state affinity results. 
 
Surface plasmon resonance and isothermal titration calorimetry most fundamental difference 
is that the former is a surface-based biosensor method whilst the latter is a solution-based 
method. The fact that biosensors require the immobilization of one of the binding partners 
onto a surface has brought about speculation that the immobilization onto a surface would 
result in artificial change of the binding constants. The perturbation could arise from 
nonspecific surface binding and limitations to the transport of analyte to and from the surface. 
Very important features included in Biacore systems that helped overcome the limitations 
mentioned are the dextran layer in the surface of sensor chips and the flow cell system used. 
The dextran layer provides a hydrophilic fluid environment where the immobilized interactant 
retains most of its rotational and some diffusional freedom. The flow cell system used by 
Biacore provides rapid delivery of a constant supply of analyte during the association phase 
and for rapid washout of the surface during the dissociation phase. The overall good 
correlation of SPR results with ITC (Fig. 29, Fig. 30) shows that immobilization onto a 
surface does not affect the binding very much. Together the two techniques delivered a very 
complete stoichiometric, kinetic and thermodynamic profile of the anti-EGFR antibodies 
studied. Their  combined utilities and corroborative use is in accordance with published 
studies (Deinum et al., 2002; Myszka et al., 2003). 
 
Static light scattering provided corroborative qualitative results that confirmed the 
stoichiometry of binding. However, the SEC separation used did not provide sufficient 
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resolution to discriminate between heterotrimers and heterodimers. Nevertheless, SLS 
analysis delivered absolute measurements of the average size of complexes formed in 
mAb/EGFR solutions. 
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8 7BCONCLUSIONS 
The applicability of SPR, ITC and SPR for the generation of meaningful quantitative data on 
binding interactions is demonstrated. Clear stoichiometric, kinetic and thermodynamic 
answers were obtained that together provide a deep understanding of the interactions on the 
molecular level. SPR provided real-time monitoring of interactions, while ITC and SLS are 
steady state techniques. Real-time monitoring of interactions was a highly interesting feature 
since it allowed determination of the binding kinetics and gave insights into the dynamic 
processes of the interdependence of different mAbs binding to EGFR. Affinity and 
thermodynamic characterization of mAb/EGFR interactions was performed both by SPR and 
ITC. SPR critics have argumented that the immobilization of one interactant onto a surface 
would result in artificial perturbation of the binding. This could explain the systematic bias 
observed for the affinity constants: KD(Biacore) were generally higher than KD(ITC), for all 
the interactions tested. However, a good overall correlation was obtained between the 
thermodynamic results of mAb/EGFR interactions from both techniques.  
 
Discrepancies were observed between ITC and SPR results of ligands/EGFR interactions. 
Due to the complexity of the ligand/EGFR interactions, experimental results are difficult to 
model in an accurate way. More than only related with the correlation between both 
determination methods, these results show the limitations of biophysical methods in the study 
of complex interactions, with many linked equilibria (Lemmon, 2009). The data treatment 
involves modelling of the experimental results and the first model of choice corresponds to 
independent binding sites and absence of linked equilibria (1:1 interaction model in SPR; one-
sites model in ITC). These models yield kinetic, affinity or thermodynamic results 
representing the average bulk interactions, however, physical significance of the values 
obtained is hardly assigned. On the other hand, the use of higher sophisticated models also 
implies the risk of low significance of results obtained. A model with more variables will 
always yield a better fit, not meaning that this model better describes the physical reality. 
 
Multiple publications have dealt with the comparability of ITC and Biacore results (Deinum 
et al., 2002; Day et al., 2002; Myszka et al., 2003). Interestingly, given that EGFR is a 
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membrane protein, one could think that the surface- and not the solution-based technique 
mimics best the in vivo situation. In principle, confirmation of results with orthogonal 
techniques can provide validation of those results and that is highly valuable for the 
experimental scientist. Beyond that, it is important to always keep in mind the conditions in 
which the results were produced and how they can be interpreted to yield answers to the 
questions asked. This study shows the combined utilities and corroborative use of SPR and 
ITC techniques; together they delivered a very complete stoichiometric, kinetic and 
thermodynamic profile of the anti-EGFR antibodies studied. 
 
This study provided for the first time clear stoichiometric evidence for the bivalent binding of 
anti-EGFR antibodies. Moreover, it was shown that the binding events taking place in both 
antibody arms are independent from each other. Bivalent binding has been related with an 
increase in the stability of antibody at the surface of tumor cells, due to avidity effects 
(Rehder et al., 2008) and the formation of antibody-mediated EGFR dimers has been related 
to a faster receptor internalization rate and consequently a faster down-regulation (Friedman 
et al., 2005).  
 
The strength of antibody/EGFR binding affinities is the result of kinetic rates and 
thermodynamic physical quantities. The kinetic and thermodynamic study of interactions 
provided for the first time a deeper understanding of the reasons behind anti-EGFR antibodies 
affinities. Cetuximab and panitumumab are strong binders, with affinities equal to or lower 
than 1 nM. Both antibodies have fast association rates and slow dissociation rates. 
Matuzumab’s 10 times weaker affinity is mainly due to a very fast dissociation rate. 
Nimotuzumab’s at least 20 times weaker affinity is mainly due to a very slow association rate. 
In thermodynamic terms, an interesting correlation was seen between large enthalpy 
contributions and weak affinities. For weaker affinity antibodies, such as matuzumab, the 
large enthalpy contribution is partially cancelled by strong entropy penalty, so that the overall 
resulting binding strength is moderate. Panitumumab, the antibody studied with strongest 
affinity, showed the smallest enthalpy contribution, however the entropy term was around 
zero. 
 
The simultaneous binding of matuzumab and cetuximab to EGFR was proven with 
stoichiometry, kinetic and thermodynamic evidence. Indeed, in vitro studies had shown a 
synergistic effect of matuzumab and cetuximab in combination (Dechant et al., 2008; Kamat 
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et al., 2008) and recent structure studies indicated that the simultaneous binding of the two 
antibodies is possible (Schmiedel et al., 2008). The simultaneous binding of matuzumab and 
nimotuzumab is reported in this study for the first time, and stoichiometric, kinetic and 
thermodynamic evidence for this is as well presented. The simultaneous binding of antibody 
combinations to EGFR has important implications for the clinical use of therapeutic antibody 
combinations. The study of the combined application of matuzumab/nimotuzumab in cell-
based models would be very interesting to see if synergic effects are also observed. Further 
investigations on the assembly states formed by EGFR complexes with antibody 
combinations would help understand the molecular basis for the synergic effects observed. If 
the rate of EGFR clearance from the cell surface is proportional to the size of EGFR-mAb 
lattices, then the bigger these lattices are, the faster and more efficiently EGFR can be down-
regulated (Friedman et al., 2005). The results of this study indicate that antibody 
combinations do not complex more than two EGFR molecules, the same number of molecules 
complexed by only one antibody type. If they are confirmed, then down regulation of EGFR 
is not likely to be the reason behind the synergic effects observed. Alternatively, synergic 
effects could be related to potent activation of complement-dependent cytotoxicity against 
EGFR-expressing cells (Dechant et al., 2008). 
 
The biophysical results obtained with nimotuzumab indicate that the solution studied has 40% 
of inactive antibody arms, what is somehow troubling having in account that the solution used 
was a market product and thus directed for clinical use. A comparability study indicated that 
the same results would be obtained by a second product vial from an independent batch and a 
completely independent supply route. The hypothesis of this vial being one unfortunate case 
was thus excluded.  
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